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1 ABBREVIATIONS 
 
APC   Antigen-presenting cell 
BSA   Bovine serum albumin 
CMIS   Common mucosal immune system  
ConA   Concanavalin A 
Cpn   Chlamydia pneumoniae 
CT   Cholera Toxin 
CTB   Cholera Toxin Subunit 
CTL   Cytotoxic effector T lymphocyte(s) 
DAB   3.3´-Diaminobenzidine 
DAMP  Damage-associated molecular pattern  
DC   Dendritic cells(s) 
DMEM  Dulbecco´s modified Eagle medium 
EDTA   Ethylendiamineteracetic acid 
ELISpot assay Enzyme-linked immunospot assay 
FACS   Fluorescence-activated cell sorting 
FasL   Fas Ligand 
FCS   Fetal calf serum 
FITC   Fluorescin Isothiocyanat 
GEEC   GPI-Enriched Endocytic Compartments 
GPI-AP  Glycosylphosphatidylinositol - anchor protein 
HBc   Hepatitis B virus core  
HBV   Hepatitis B Virus 
HBVc   Hepatitis B Virus core  
IC31®   Intercell´s adjuvant consisting of L-KLK and ODN1a 
i.d.   intradermal 
IFN   Interferon 
IFN-    Interferon-gamma 
IL   Interleukin 
i.m.   intramuscular 
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i.p.   intraperitoneal 
ISCOM  Immunostimulating complex 
KLK   KLK(L)5KLK consisting of L-amino acids (L-KLK) 
LN   Lymph nodes 
LNC   Lymph node cells 
LSM   Lymphocyte Separation Medium 
M cells  Microfold cells 
MACS  Magnet-assisted cell sorting 
MALT   Mucosa-associated lymphoid tissues  
MHC   Major histocompatibility complex  
NALT   Nasopharynx-associates lymphoid tissue  
NGF   Nerve growth factor  
NOD    nucleotide oligomerization domain  
ODN   Oligodeoxynucleotide(s) 
ODN1a Phosphodiester-substituted single-stranded ODN containing 
13 deoxy (-iosine, -cytosine) motifs [o-d(IC)13] 
O/W   Oil-in-water emulsion 
PBMC  Peripheral Blood Mononuclear Cell 
PBS   Phosphate-buffered saline 
PE   Phycoerythrine  
PMA   Phorbol-12-myristate-13-acetete 
PRR   Pattern-recognition receptor 
QC-IV   Quality Control – In Vivo  
SA-HPO  Streptavidin-horseradish peroxidase 
s.c.    subcutaneous 
SFC   Spot forming cells 
SOP   Standard operation procedure 
SPLCs  Spleen cell(s) 
SVN   Survivin peptide 
TAA   Tumor associates antigens 
TCR   T cell receptor 
TH   T helper cell(s) 
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TNF   Tumor necrosis factor 
TNF-α   Tumor necrosis factor-alpha 
TLR   Toll-like receptor 
TRP-2180-188  Tyrosinase-related protein-2180-188 
W/O   Water-in-oil emulsion 
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2 ABSTRACT 
Intercell AG has developed a novel bi-component adjuvant, called IC31®. It 
is a synthetic TLR9 agonist that has been shown to efficiently elicit dominant TH1-
type in a mixed TH1/TH2-type immune response.  
This study at hand was designed to characterize and determine the ability 
of IC31® to induce potent CD8+ T cell responses against clinically relevant cancer 
peptides upon systemic and mucosal administrations. 
Therefore, six promising tumor-associated antigens were selected for 
testing their immunogenicity in combination with this novel adjuvant. Distinct 
Survivin and  Tyrosinase-related protein 2 (TRP-2)  derived peptides with defined 
human and mouse MHC class I molecule restricted CD8+ epitopes, which makes 
them highly attractive as target for T cell based immune strategies against cancer, 
were used as antigens for immunization studies. The results of the screening for 
immunogenicity demonstrated the efficiency of the classical formulation of IC31® in 
supporting antigen-specific immune responses by specifically increasing IFN-  
production against SVN19-28, SVN57-64 and TRP-2180-188 peptides in central lymphoid 
organs. 
Furthermore, differences on the potency of IC31® nano in terms of 
inducing CD8+ T cell responses by the use of different immunization routes 
(subcutaneous, intramuscular, intradermal and intraperitoneal) were determined in 
adjuvanted SVN57-64 and TRP-2180-188 vaccinated C57BL/6 mice. Groups of 
animals immunized with SVN57-64 or TRP-2180-188 peptides and IC31
® elicited higher 
IFN-  production in comparison to groups vaccinated with antigen only after 
injection with all the above mentioned routes. Subcutaneous (s.c.) injection was 
superior to all other routes in terms of inducing antigen-specific responses in vivo. 
Both peptides formulated with the adjuvant were utilized for immunization studies 
but adjuvanted SVN57-64 failed in eliciting antigen-specific CD8
+ T cell responses. 
Therefore SVN19-28 was used as specific Survivin derived peptide for further 
experiments. 
Parallel to this study, the efficacy and efficiency of IC31® nano in inducing  
cellular immune responses against SVN19-28 and TRP-2180-188 peptides upon 
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mucosal (intranasal) as well as systemic applications (intradermal) was 
determined.  
The data of the intradermal vaccination study revealed the high potency of 
IC31® in inducing systemic TRP-2180-188 specific cytotoxic CD8
+ T responses in 
central lymphoid organs as well as at mucosal sites. Further, the data upon 
systemic (i.d. and s.c) application of the vaccine showed the induction of sustained 
long lasting immune responses by activation of memory CD8+ T cell without the 
help of CD4+ T cells in spleens and lymph nodes. 
Furthermore, IC31® improved the induction of a high systemic TH1 immune 
response in vivo upon systemic intradermal route vaccination using the second 
tumor-associated antigen candidate, the Survivin derived peptide epitope SVN19-28. 
The obtained data revealed that effector CD8+ T cells were not polyfunctional 
because only IFN-  and any other cytokine production was evaluated in central 
lymphoid organs and at mucosal sites. 
While IC31® nano demonstrated the great potency to improve the cellular 
immune response upon systemic application, mucosal administration of the 
adjuvant never supported the induction of an antigen- specific CD8+ T cell immune 
response against the cancer peptides tested. Therefore, intranasal administration 
seemed not to be a promising immunization route against cancer.  
Altogether the results indicated the high efficiency of IC31® nano in 
eliciting a systemic CD8+ T cell immune response in central lymphoid organs and 
at mucosal sites following intradermal vaccination. Additionally, TRP-2180-188 and 
SVN19-28 are suitable candidates for the development of a vaccine against cancer. 
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3 ZUSAMMENFASSUNG 
Intercell AG entwickelte ein aus zwei Komponenten bestehendes Adjuvant 
IC31®. Es ist ein synthetischer TLR9 Agonist, der eine dominierende TH1 in einer 
gemischten  TH1/TH2 Immunantwort auslöst.  
Diese Studie wurde zur Charakterisierung und Bestimmung von einer 
IC31®  induzierten CD8+ T Zellen-Immunantwort gegen klinisch relevante 
Krebspeptide nach systemischer und mukosaler Applikation geplant. Dafür wurden 
sechs vielversprechende CD8+ Epitope enthaltende Tumor- assoziierte Peptide 
ausgewählt, die des Weiteren hinsichtlich ihrer Immunität in Kombination mit 
IC31® getestet wurden. Survivin und Tyrosinase-related protein 2 (TRP-2) 
stammende Peptide besitzen definierte humane und murine MHC Klasse I 
zugehöriges CD8+ Epitope und dienen als Target für eine T Zellen-basierende 
Immunstrategie gegen Krebs. Diese Peptide wurden als Antigene für die 
angewendeten Immunisierungsstudien verwendet. Die erhobenen Resultate 
zeigten das Potential von klassischem IC31®, eine erhöhte IFN-  Produktion 
gegen  SVN19-28, SVN57-64 und TRP-2180-188 in zentralen lymphoiden Organen zu 
induzieren. 
Aufgrund der Ergebnisse der erhobenen Daten wurden folglich die 
Unterschiede in der Effizienz von IC31® nano im Bezug auf die Einleitung einer 
CD8+ T Zellen-Immunantwort in Kombination mit zwei der vielversprechenden 
Peptide (SVN57-64 und TRP-2180-188) bei der Verwendung unterschiedlicher 
Applikationsrouten (subkutan, intramuskulär, intradermal und intraperitoneal) 
untersucht. Alle angewendeten Routen lösten in SVN57-64 oder TRP-2180-188 in 
Kombination mit IC31® immunisierten Tieren, höhere IFN-  Produktionen im 
Vergleich zu Antigen allein immunisierte C57BL/6 Mäuse aus. In zentralen 
lymphoiden Organen induzierte subkutan (s.c.) Injektion im Vergleich zu allen 
anderen Routen die höchste Antigen-spezifische Immunantwort in vivo. Beide 
Peptide wurden für folgende Experimente verwendet, jedoch konnte keine weitere  
Antigen-spezifische CD8+ T Zellen-Immunantwort im Bezug auf Adjuvant und 
SVN57-64 Applikation detektiert werden. Deshalb wurde für weitere 
Immunisierungsstudien SVN19-28 als spezifisches Survivin Peptide verwendet. 
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Aufgrund der vielversprechenden Ergebnisse der unterschiedlichen 
Immunisierungsrouten in C57BL/6 Mäusen, wurde der Fokus dieser Studie auf 
die Charakterisierung des Potenzials von IC31® nano, eine systemische SVN19-28 
oder TRP-2180-188 spezifische zelluläre Immunantwort mittels mukosaler 
(intranasal) sowie systemischer (intradermal) Applikationen auszulösen, gelegt. 
Die erhobenen Resultate der intradermalen Impfstudien zeigten, dass 
IC31® aufgrund seiner hohen Effizienz, systemische TRP-2180-188 spezifische 
cytotoxische CD8+ T Zellen in zentralen lymphoiden Organen, sowie in 
mukosalen Bereichen aktiviert. 
Zusätzlich wurde in dieser Studie das Potenzial von IC31® nano 
diesbezüglich des Auslösen einer langanhaltenden TRP-2180-188 spezifischen CD8
+ 
T Zellen-Immunantwort nach systemischer (i.d. und s.c.) Applikation, mittels IFN-  
Produktion in zentralen lymphoiden Organen getestet. Die Daten demonstrierten, 
dass zentrale CD8+ Gedächtniszellen ohne die Hilfe  von CD4+ Zellen in Milzen 
und Lymphknoten gebildet und nach ex vivo Restimulierung mit dem Antigen 
erneut aktiviert wurden. 
Des Weiteren zeigte IC31® hinsichtlich des zweiten Krebspeptids, SVN19-28 
die Induktion einer hohen systemischen TH1 Immunantwort folglich systemischer 
intradermalen Impfung in vivo. Die erhobenen Daten weisen die Aktivierung von 
Effektor CD8+ T Zellen auf, die jedoch aufgrund IFN-  und keiner weitere 
Cytokinproduktion nicht polyfunktional in zentralen lymphoiden Organen sowie in 
mukosalen Bereichen sind. 
Die erhobenen Daten dieser Studie zeigten, dass IC31®  als systemisches 
aber nicht als mukosaler Adjuvant eine Antigen spezifische systemische CD8+ T 
Zellen-Immunantwort in lymphoiden Organen, sowie in den Lungen auslöst. Die 
intranasale Applikation erwies sich als keine aussichtsreiche Immunisierungsroute.  
Zusammengefasst zeigen die Ergebnisse einerseits das große Potential 
des Adjuvanten IC31® als Bestandteil dermaler Impfstoffe eine systemische CD8+ 
T Zellen-Immunantwort in zentralen lymphoiden Organen sowie in mukosalen 
Bereichen gegen spezifische Krebspeptide auszulösen. Des Weiteren erweisen 
sich TRP-2180-188 und SVN19-28 als bevorzugte Impfstoffkandidaten.  
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4 INTRODUCTION 
4.1. Adjuvants 
  Adjuvants by definition are substances or molecular complexes that 
enhance, sustain and accelerate antigen-specific immune responses and therefore 
improve the efficiency of vaccines (1-4). 
 Vaccines based on some pathogens, like bacteria and viruse as well as 
vaccines based on proteins and peptides show insufficient immunogenicity when 
administered alone. Therefore the addition of an adjuvant is necessary to improve 
the evocation of protective and long lasting immune response (2, 5). 
Effective adjuvants are on the one hand immunostimulatory agents (Toll-
like receptor (TLR) ligands, cytokines, saponins and bacterial exotoxins) that 
stimulate immune responses (T-helper (TH) 1 or TH2 immune response), or on the 
other hand carriers (mineral salts, emulsions, liposomes, visosomes, 
immunostimulating complexes (ISCOM)) that present the antigen to the immune 
system, including the formation of a depot and controlled release of the antigen. 
Figure 1 summarizes the main types of adjuvants and their specific properties as 
immunostimulator and/or carrier (1-3). 
Alum (mineral salt) and MF59TM (a squalane oil-in-water emulsion) are 
adjuvants with different properties. Both are approved for human use and enhance 
induction of TH2 immune response
 (2, 3). Cholera Toxin (CT) originally derives 
from Vibrio cholera. It is an enterotoxin that as effective adjuvant enhances 
mucosal and systemic TH2 cell responses to co-injected antigens (4, 6). It is 
composed of a pentameric B subunit (CTB) that binds to GM-1 receptors, while 
subunit A (CTA) is responsible for toxicity. CTB has the capacity to act as efficient 
adjuvant by improving induction of an antigen-specific cytotoxic T lymphocyte 
(CTL) response via intranasal immunization route. The main problem for the use of 
CTB as adjuvant in humans is the high toxicity. This is not the case in mice and 
therefore it was used as an additional adjuvant control for intranasal immunization 
route during this study (2, 3, 7, 8) . 
Alum and M59TM are less attractive for vaccines against intracellular 
pathogens and cancer that require the induction of antigen-specific T cell immune 
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responses. Therefore, Intercell AG has developed an adjuvant, called IC31® that 
was designed to induce a potent and sustain cellular and humoral immune 
response in mice and humans (9-12). 
 
 
 
Figure 1: Main types of adjuvants. These are adjuvants that contain single or both properties 
(carrier and/or immunostimulator). Some compounds (red background) have the ability to direct the 
responses towards T helper (TH) 1 or TH2 immune response. (2) 
 
 
4.1.1. IC31® 
 IC31® adjuvant is a potent immunostimulator inducing antigen-specific 
cellular and humoral immune responses without eliciting any pro-inflammatory side 
effects (10, 11, 13). The bi-component adjuvant is a mixture composed of a 
cationic peptide KLKLLLLLKLK (KLK5KLK; KLK) and a single-stranded DNA 
phosphodiester, containing dimeric deoxy-Inosine/deoxy-Cytosin repeats (ODN1a; 
5’ICICICICICICICICICICICICIC-3’). These two components are combined in a 
molar ratio of 25:1 of KLK:ODN1a and generate in a synergistic way the 
immunostimulatory effect of IC31® (10, 14). 
KLK is a synthetic derivate of a cationic antimicrobial peptide (CAMP) that 
mimics structural elements originally derived from sapecin B. (12, 15) The 
immunopotentiating effect of IC31® derives from KLK that has on the one hand the 
potency to induce antigen-specific type-2 T cell immune responses and on the 
other hand the capacity to promote the association of antigens to antigen 
presenting cells (APCs). This APC activation specifically leads to up-regulation of 
surface major histocompatibility complex (MHC) molecules and co-stimulation 
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molecules such as CD40, CD80 (B7.1) and CD86 (B7.2). The ability of KLK to 
activate APCs is more efficient in the presence of ODN1a (10, 13, 15, 16). 
Beside APC activation, KLK has the potential to facilitate the cytoplasmic 
delivery of ODN1a and antigen by an APC, such as Dendritic cells (DC) (10, 15, 
17). Therefore, the cationic peptide assembles into a β-sheeted aggregate that 
enhances complex formation by entrapping the oligonucleotide (ODN1a) and the 
antigen. Moreover, the process of delivery is enhanced by the specifically 
association of the generated complex with the negatively charged lipid rafts on the 
DC surface. This interaction leads through an endocytotic uptake (mostly clathrin-
dependent, caveolae-dependent or GEEC-pathway) and internalization of ODN1a 
and antigen into the DC cytosol. After delivery, the complex disassembles and 
ODN1a and the antigen are transported to their intracellular targets, while KLK use 
GPI-AP/GEEC recycling system to interact with the plasma membrane in the cell 
periphery (17, 18). 
Furthermore, the cationic peptide is able to mediate the formation of a 
vaccine depot at the injection site to control and maintain a long-term antigen and 
adjuvant release (15). 
The second component of IC31® is a non-CpG oligonucleotide (ODN1a) 
that represents its adjuvantive effects as a synthetic TLR9 agonist by signaling via 
TLR9/MyD88 signaling pathway. Thereby, the transcription factor NF-κB is 
activated and initiates antigen specific type 1 T cell immune response (9, 10).  
Intercell AG has established two different formulations of IC31® which are 
constituted of the same single components (KLK and ODN1a), but differ in their 
particle size.  The classical formulation of IC31® generates a 5-10µm complex. On 
the other hand the nano formulation of the bi-component adjuvant forms a particle 
with a size less than 200nm. The advantages of nanoparticulated adjuvantive 
systems are the improved uptake of vaccines by APCs and therefore the 
promotion of an effective immune response as well as the use for different 
therapeutic route vaccinations (19, 20). 
The single components, KLK and ODN1a from the novel 
immunopotentiator IC31® enhances in combination with an immunogenic antigen, 
DC activation that results in a potent antigen-specific type 1 dominated mixed type 
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1/type 2 immune responses that are necessary for priming CD4+ Th, cytotoxic T 
lymphocytes (CTL) and B cells (IgG1 and IgG2a) (5, 10, 16). 
 
 
4.2. T cell activation 
 IC31® initiates an effective more type 1 than type 2 T cell immune 
response, including activation of naïve T cells which requires antigen uptake by an 
APC. APCs, such as DC start maturation after binding pathogen association 
molecular pattern (PAMP) to pattern recognition receptors (PRR), such as Toll-like 
receptors (TLR), nucleotide oligomerization domain (NOD)-like receptors and 
others. This APC activation results in combination with inflammatory cytokines 
(TNF and type I inerferones) in switching DCs from a inactivated and resting to an 
activated state that leads through up-regulation of MHC molecules, expression of 
co-stimulation molecules as well as expression and secretion of cytokines and 
chemokines. These facilities allow DCs to migrate from the thymus to the 
secondary lymphoid organs where they complete maturation and present the 
processed antigen to naïve T cells (10, 21, 22). 
Antigen presentation on the cell surface of APCs and antigen recognition 
by CD4+ and CD8+ T cells is MHC molecule restricted. MHC molecules are 
subdivided into two classes, class I and class II, which mediate antigen 
presentation by using different antigen processing pathways. MHC class I present 
8-10 amino acid long peptides  derived from intracellular protein antigens to CD8+ 
T cells, while MHC class II molecules presents processed peptides from 
extracellular protein antigens to CD4+ cells. Furthermore, the antigen/MHC 
molecule complex is recognized by a surface αβ-T –cell receptor (TCR) on T cells. 
For a full T cell activation the association of co-stimulation molecules like CD80 
(B7.1) and CD86 (B7.2) with CD28 on the surface of CD8+ T cells and CD40 
interaction with CD40L on the surface of CD4+ T cells, are efficient. These 
interactions affirm fully functional T cell activation. CD80 (B7.1)/CD28 association 
provokes survival and proliferation of CD8+ effector T cells, while CD40/CD40L 
interaction plays a role in enhancing and controlling B cell as well as CD8+ T cells 
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activation (21, 22). Figure 2 summarizes the main types of effector T cells and 
their specific functions. 
After T cell activation by APCs, distinct cytokine production enhances 
naïve T cell proliferation and differentiation.  The activated T helper cells (CD4+) 
proliferate and differentiate into effector cells and can be distinguished between 
TH1 and TH2 cells. While TH1 cells secrete cytokines such as Interleukin (IL)-2, 
Interferon (IFN)- , Tumor necrosis factor (TNF)-α and granulocyte macrophage 
colony stimulating factor (GM-CSF) that promote the activation of macrophages 
and cytotoxic T cells as well as the production of opsonizing antibodies like IgG2a 
and IgG2b, for pathogen depletion. TH2 express cytokines, such as IL-4, IL-5, IL,6, 
IL-10 and IL-13 that play key roles in humoral immunity by supporting 
differentiation and proliferation of naïve B cells as well as production of non-
opsonizing antibodies (23-25). 
CD8+ T cells differentiate to cytotoxic T lymphocytes (CTL) that are 
effector cells which induce potent cytoloytic killing mechanisms against tumors and 
intracellular pathogens, including viruses, some bacteria and protozoa (26). CTLs 
are cytotoxic effector CD8+ T cells and therefore antigen presentation by APCs is 
MHC class I restricted. CTL stimulation leads to cytokine production such as IFN- , 
IL-2 as well as TNF-α and TNF-β. These cytokines mediate increased 
macrophage activation, while IL-2 secretion and IL-2 receptor expression is 
elicited by presentation and recognition of an antigen/MHC complex. The cytokine 
IL-2 binds to IL-2 receptor with high affinity and triggers in an autocrine manner 
proliferation and differentiation of a naïve CD8+ T cell into an effector cytotoxic T 
cell. In some instances CD4+ T cells that are MHC class II restricted, secrete IL-2 
in a paracrine manner and thereby supports CD8+ effector T cell activation (24, 
26). Therefore, CD4+ T helper cells play a key role to generating and maintaining 
long-lasting humoral and cellular immune responses (25) . 
CTL are effector cells that provoke efficient and rapid cell death of the 
target cell by the release of lytic components (perforine, granzymes) or direct cell-
cell interaction (Fas ligand (FasL)). Perforine and granzymes are stored in 
cytotoxic granules that are transported to the surface of the target cells after CTL 
activation. Perforin, a pore-formin protein, perforates the cell membrane and 
 
18 
 
allows cytotoxic components and granzymes (serin proteases) to enter the target 
cell where it degrades DNA by initializing an enzyme cascade. Specifically, 
Granzyme B is one of the most efficiently granzymes and has the capacity to 
promote apoptotic cell death of the target cell by caspase activation (23, 27).  
An alternative killing mechanism of CTLs is a cell-cell interaction (Fas-
FasL). Fas receptor on the target cell and FasL on CTLs belongs to the tumor 
necrosis factor (TNF)/nerve growth factor (NGF) receptor family and are the main 
components of this alternative cytotoxic pathway. The ligand, FasL stimulates after 
binding the Fas receptor on the infected target cell, a caspase cascade that 
furthermore elicit DNA degradation and apoptotic cell death of the target cell (24, 
28). 
 Proliferation phase of antigen-specific cytolytic CD8+ T cell response is 
followed by the formation of memory cells. Memory cells increase the protection of 
the host by qualitatively better and more rapid usage of effector function upon 
antigenic stimulation than naïve T cells. Memory cells derive from effector T cell 
and have protective capacity. They are subdivided into two subtypes based on 
their anatomical location: central memory cells (TCM) and effector memory cells 
(TEM). TCM are located in secondary lymphoid organs, such as spleens, lymph 
nodes and blood that contain a great expansion potential. They contain CD62L 
and CCR7 as main markers in comparison to CD62L-CCR7- TEM cells that exhibit a 
rapid cytotoxic capacity. TEM cells are specifically located in non-lymphoid tissues 
(e.g., liver, lung, intestine) and at mucosal sites (21, 29). 
However, an effective type 1 T cell immune response includes the 
activation of CTL against intracellular pathogens as well as tumor-associated 
antigens (TAA) (10). 
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Figure 2: Main types and function of effector T cells. Adapted from Janeway, Tracers and 
Walport; Immunobiology: The Immune System in Health and Disease, Fifth Edition, Garland 
Science 2001. 
 
 
4.3. Targets for T cell based immune strategies 
 The aim of cancer vaccine is to use tumor-associated antigens (TAA) as 
target and mediate an antigen-specific T cell immune response against cancer 
(30). 
 The largest number of CTL- responses has been identified for melanoma 
associated TAAs (31). One of these TAAs is the Tyrosinase-related protein-2 
(TRP-2). It is a 519-amino-acid membrane protein including dopachrome 
tautomerase activity. While TRP-2 is involved in melanin synthesis and 
melanocyte differentiation in normal adult cells it is also widely expressed in 
melanoma patients (32, 33). This cancerogen expression of the protein results in 
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overcoming of self-tolerance and thereby in elicitingof a TRP-2 specific CTL anti-
tumor immunity. TRP-2180-188 is one specific CD8
+ epitopes of TRP-2. It is 
presented by MHC class I haplotypes (HLA-A*0201 and H-2 Kb) that is recognized 
by both human and murine CTLs and it is regarded as one of the most promising 
TAA candidates for an anti-tumor vaccine (30, 34). 
 Most of the identified CD8+ epitope peptides are melanocyte specific and 
cannot be used for cancer vaccine against nonmelanocyte derived tumors. 
Therefore, Survivin (SVN) a small, 16.5-kDa protein and member of inhibitor of 
apoptosis family, is involved in cell cycle progression-, cell proliferation- and cell 
death pathways. It is characterized as a TAA that has the capacity to mediate anti-
tumor CTL immune responses against solid tumors, such as lung, breast, prostate, 
colon, and pancreas cancer as well as hematopoietic malignancies. Therefore 
peptides of the protein represent a promising target for a cancer vaccine. Survivin 
is beside the appearance in different types of cancer also frequently expressed in 
normal adult cells. This leads to the overcome of self tolerance to elicit CTL anti-
tumor immunity (35, 36). Survivin peptides are presented such as TRP-2 by 
mouse H-2 Kb and human HLA-A201 MHC class I haplotypes on DCs. Survivin is 
a protein that contains different CD8+ epitopes, like SVN82-89 and SVN57-64 peptide 
that are homologous to human peptide and mediates specific CTL immune 
response. . A further specific CD8
+ epitope of the SVN protein is the SVN53-67 that 
generates both CD4+ T helper and CD8+ CTL immune response (37). 
 Both characterized tumor-derived proteins, TRP-2 and SVN contain 
defined human and murine MHC class I molecule restricted CD8+ epitops that 
makes Survivin derived peptides and TRP-2180-188 as target highly attractive for T 
cell based immune strategies against cancer (30, 36). 
 Furthermore, Hepatitis B Virus (HBV) induces acute and chronic hepatitis 
that results in the development of hepatocellular cancer. The nucleocapsid of HBV 
is a 27nm particle composed of multiple single polypeptides, called Hepatitis B 
virus core (HBc or HBVc). HBc can be used as a specific target for the immune 
system to regulate infection (38). HBc antigen generates spontaneously 
immunogenic particles that are presented by an APC-like B cell and elicit Th1 and 
CTL responses. The activated CD4+ T helper cells help on the one hand in CTL 
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stimulation as well as in developing a long-term CD8+ T cell memory response (39-
41). Therefore it was used as an additional antigen to determine the long lasting 
immune response of CD8+ T cells during this study. 
 
 
4.4.  Mucosal immune system and intranasal vaccination 
The mucosal immune system includes the epithelial surface of the genitor-
urinary, intestinal and upper and lower respiratory tract. The epithelium generates 
a physical barrier that forms the first line of immunological defense and thereby 
avoids pathogen invasion. However, epithelial cells have also the ability to 
recognize PAMPs by binding to PRRs, such as TLR. This results in DC and 
macrophages activation by cytokine and chemokine secretion as well as initiation 
of innate and antigen-specific adaptive immune responses (42, 43). Previous 
studies showed that mucosal DCs contain TLR9 in early endosomes that 
recognizes CpG region in bacterial and viral ssDNA as well as IC31® which 
contains a TLR9-mediated immune-enhancing activity. This capacity utilizes IC31® 
to act as systemic as well as mucosal adjuvant (4, 10, 44). 
Anigen-specific mucosal immune responses are initiated by Microfold (M) 
cells that are found in the follicle-associated epithelium and are overlaid from 
mucosa-associated lymphoid tissues (MALT). M cells are responsible for antigen 
delivery by transepithelial vesicular transport (transcytosis) from the aerodigestive 
lumen to the Nasopharynx-associated lymphoid tissue (NALT) in the respiratory 
tract or Peyer´s patches in the gastrointestinal tract. Both, NALT and Peyer´s 
Patches are known as IgA inductive sites and are the main components of MALT 
(2, 20, 42). All immunocompetent cells (T cells, B cells, Th cells, CTLs and antigen 
presenting cells) that are required for the induction of an effective immune 
response, are concentrated in these specific lymphoid tissues. The antigen 
activated B and T cells migrate from the IgA inductive sites via lymphatic system 
and circulation through mucosal effector sites, such as lamina propria in 
respiratory-, intestinal- and the reproductive tract. The common mucosal immune 
system (CMIS) allows communication between organized mucosa-associated 
lymphoid tissues and effector sites. At the effector sites the induction of antigen-
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specific mucosal antibody (IgA and IgG) responses as well as TH1-cell- and CTL-
dependent immune responses was determined in previous observations. IgA is the 
primary immunoglobulin (Ig) on mucosal surfaces and protects the host from 
pathogen invasion at these sites (4, 42, 43, 45, 46). 
Studies have demonstrated that mucosal immune responses are most 
locally protective when induced by mucosal vaccine amplification (oral, intranasal 
(i.n.), intrarectal or intravaginal). By the use of oral or intranasal administration, 
mucosal vaccines are delivered safely and elicit strong antigen-specific mucosal 
and systemic immune responses. These vaccines avoid pathogen invasions at 
mucosal sites as well as expansion into the systemic circulation by inducing 
antigen-specific TH1 and/or TH2 immune responses (4, 43). 
Intranasal route vaccination is a promising immunization strategy in terms 
of lymphoid tissue (NALT) in the nose that indicates in advance cell and humoral 
mediated antigen-specific immune responses. A further advantage of intranasal 
vaccine administration is the requirement of much smaller doses of antigens to 
induce mucosal and systemic immune responses (42). 
 
 
4.5.  Cutaneous immune system and intradermal vaccination 
The skin is one of the largest organs of the mammalian body. It forms a 
physical barrier and thereby avoids pathogen invasions. Furthermore, the skin 
plays also an important role in eliciting antigen-specific adaptive immune 
responses that includes specific immune cells, such as mast cells, macrophages, 
specific dendritic cells (Langerhans cells and dermal dendritic cells) and T cells 
(47). 
The skin is composed of two layers: the epidermis, that includes 
keratinocytes and Langerhans cells (LCs) that generates a physical barrier, and 
the dermis, which contains APCs and is necessary for thermoregulation, immune 
surveillance and blood supply for the epidermis (48, 49). 
However, the epidermis contains a high density of specific DCs, called 
Langerhans cells (LC). These cells express different TLRs, especially TLR9 on the 
early endosomes of LCs. TLR9 plays an important role to guide the choice of 
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different adjuvants, like the TLR9 agonist IC31® (10, 50, 51). LCs are well 
characterized DCs in humans and mouse and differ phenotypiclly from antigen 
presenting cells in other tissues, as well as in terms of their function. LCs aims the 
induction of CTL and play an essential role for anti-tumor immunity in vivo (52).  
LCs are immature DCs that are activated by antigen binding to specific 
PRRs. By capturing and antigen processing, maturation starts by expressing MHC 
class I or class II and co-stimulatory molecules beside down regulation of Langerin 
and E-cadherin expressions on the cell surface. The mature cells migrate by 
chemotxis to secondary lymph nodes where they efficiently present the antigen to 
T cells and initiate antigen-specific immune responses. Further, the maturation 
and migration of LCs to the paracortical region (T cell zone) of lymph nodes is 
stimulated by secretion of cytokines such as IL-1 β and TNF-α (50, 51, 53-55). 
Further advantages of the skin are the easy accessibility and high 
immunogenicity which makes it attractive for intradermal vaccine application. 
Intradermal route is a simple, rapid and safe vaccination strategy (54).  
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5. RESULTS 
5.1.  Initial screening for immunogenicity of antigenic peptides 
formulated with IC31®  
A reasonable argument for an initial screening for immunogenicity of 
tumor-associated antigens with IC31® was the limited information on the efficacy 
and efficiency of this novel adjuvant in eliciting potent CD8+ T cell responses 
against clinically relevant antigens. Therefore, this study was designed to 
determine the immunogenicity of IC31® adjuvanted Survivin and Tyrosinase-
related protein-2 derived peptides. Six promising tumor-derived peptides were 
selected based on their defined human and murine MHC class I molecule 
restricted CD8+ epitope that makes them highly attractive as target for cytotoxic T 
cells (CTLs) responses (30, 34, 37). 
Therefore, an initial screening was set up using tumor-associated 
antigens, namely SVN18-27, SVN19-28, SVN57-64, SVN82-89, SVN53-67 and TRP-2180-
188, were tested IFN-  ELIspot assay was used to observe differences in antigen-
specific T cell responses induced by those antigens in combination with IC31®.   
The obtained IFN-  ELIspot data indicated that mice vaccinated with 
SVN19-28 (IATFKNWPFL), SVN57-64 (CFFCFKEL) and TRP-2180-188 (SVYDFFVWL) 
and adjuvanted in IC31® , elicited significant CD8+ T cell responses in spleens 
(Figure 3A) and lymph nodes (iliac) (Figure 3B) in comparison to the negative 
control group, animals injected with IC31® alone. 
In summary, the obtained data indicate that SVN19-28, SVN57-64 and TRP-
2180-188 when immunized with classical IC31
® were highly immunogenic in central 
lymphoid organs in comparison to all other adjuvanted Survivin derived peptides. 
Different irrelevant peptides where further used to avoid cross-presentation.   
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 Figure 3. Analysis of CD8
+
 T cell response upon 2
nd
 s.c. co-injection of distinct tumor- 
derived peptides with classical IC31
®
 by IFN-  ELIspot assay. C57BL/6 mice were immunized 
on day 0 and 14 s.c. (100µl, tail base) with different antigens (60µg) plus classical IC31
®
 (a mixture 
of 100nmole KLK and 4nmole ODN1a in 10mM Tris/ 135mM NaCl buffer). For control purpose, 
mice were injected with classical IC31
®
 only. (A) Spleens and (B) lymph nodes (iliac) were 
harvested on day 7 after second immunization. Cells from each group were plated in triplicates at 
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5x10
5
 cells/well and ex vivo restimulated with the specific relevant antigen (SVN18-27, SVN19-28, 
SVN57-64, SVN82-89, SVN53-67 and TRP-2180-188; 1µg/ml) and with an irrelevant antigen (TRP-2180-188 
for Survivn peptides and SVN57-64 for TRP-2180-188; 1µg/ml). Medium was used as negative control. 
IFN-  production in spleen and lymph node cells was determined 24 hours after restimulation in an 
ELIspot assay. The results are shown as number of spot forming cells (SFC)/1x10
6
 total cells ± SD. 
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5.2.  Determination of CD8+ T cell mediated immune responses 
in central lymphoid organs after immunization with TRP-
2180-188 and IC31
® in mice vaccinated by different injection 
routes 
The obtained results from the screening for immunogenicity of different 
tumor-derived peptides revealed that TRP-2180-188, SVN57-64 and SVN19-28, in 
combination with the classical formulation of IC31® where highly immunogenic. To 
investigate differences on the efficacy and efficiency of IC31® nano in the induction 
of a potent antigen-specific CD8+ T cell response in spleens and draining lymph 
nodes, different injection routes and the nano formulation of IC31® were used. 
IC31® nano is composed of the same single components as the classical 
formulation (L-KLK and ODN1a), but the mean particles forms a size of >200nm. 
For all following experiments the nano formulation of IC31® was used. 
To obtain CD8+ T cell responses in central lymphoid organs, C57BL/6 
mice were vaccinated three times with TRP-2180-188 formulated with IC31
® by 
Bernhard Roeder of the Quality Control – In Vivo (QC-IV) department, at two-week 
intervals (d0 and 14 and 28), subcutaneously (s.c.) at the tail base, intramuscularly 
(i.m.) at the hind limbs, intradermally at the tail base and intraperitoneally (i.p.). For 
control purpose, mice were immunized with antigen only. On day 12 after second 
and third immunization, spleens and draining lymph nodes were harvested by 
Bernhard Roeder and single cell suspensions were prepared. IFN-  ELIspot assay 
and Intracellular Cytokine Stainings were performed as described in Material and 
Methods. 
The ELIspot data indicate that all different TRP-2180-188 and IC31
® route 
vaccinated mice, elicited high CD8+ T cell responses in central lymphoid organs in 
comparison to peptide alone vaccinated mice.  After the third immunization all 
antigen plus adjuvant immunized mice produced a significant higher amount of 
IFN-  in spleens (Figure 4A) and draining lymph nodes (Figure 4B) than after the 
second injection (Figure 5). 
 Regarding the results of i.m. vaccinated mice, which were twice 
immunized intramuscularly and once intradermally, no significant IFN-  production 
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was observed in inguinal lymph nodes, although a CD8+ T cell response was 
observed in spleens on day 12 after third injection. These IFN-  ELIspot data 
indicate that mixed vaccination routes did not effectively induce an immune 
response in draining lymph nodes. 
Figure 5 compares IFN-γ production in spleens (Figure 5A) and lymph 
nodes (Figure 5B) of TRP-2180-188 and IC31
® vaccinated C57BL/6 mice by the use 
of different injection routes over 42 days. In central lymphoid organs, s.c. injection 
was superior to all other routes in terms of inducing antigen-specific responses in 
vivo. The IFN-γ production from splenocytes in ELIspot was comparable with the 
Intracellular Cytokine Staining (data not shown). 
In summary, using different routes of vaccination with TRP-2180-188 and 
IC31®, induced a strong antigen-specific T cell response after the third 
immunization especially the s.c. injected groups. 
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Figure 4. IFN-  ELISpot analysis of CD8
+ 
T cell responses upon immunization with TRP-2180-
188 and IC31
®
 in central lymphoid organs. C57BL/6 mice were immunized on day 0, 14 and 28, 
s.c. (100µl; tail base), i.m. (50µl/hind limb), i.d. (2x50µl, tail base) and i.p. (100µl) with TRP-2180-188 
(60µg) plus IC31
®
 nano (a mixture of 100nmole KLK and 4nmole ODN1a in 2.5mM Tris buffer). For 
control purpose, mice were injected with antigen only. (A) Spleens and (B) draining lymph nodes 
were harvested on day 12 after third immunization. Cells from each group were plated in triplicates 
at 2.5x10
5
 cells/well for spleens and at 5x10
5
 cells/well for draining lymph nodes and ex vivo 
restimulated with the relevant antigen (TRP-2180-188; 1µg/ml; red) and with an irrelevant antigen 
(SVN19-28; 1µg/ml; green). Medium was used as negative control. IFN-  producing in spleen and 
draining lymph node cells was determined 24 hours after restimulation in an ELIspot assay.  The 
results are shown as number of spot forming cells (SFC)/1x10
6
 total cells ± SD. 
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Figure 5. Injection route comparison of IFN-γ production in lymphocytes of vaccinated mice. 
C57BL6 mice were injected three times on day 0, 14 and 28, s.c., i.d. and i.p. with TRP-2180-188 
(60µg/mouse) plus IC31
®
. On day 26 and 42 organs were removed and cells harvested. IFN-γ 
production on ELIspot in spleen (A) and draining lymph node cells (B) was determined. The results 
are shown as the number of spot forming cells (SFC)/1x10
6
 total cells ± SD. The arrows indicate 
immunization time points.  
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5.3. Identification  of splenic CD8+ T cell meditated immune 
responses in mice vaccinated with SVN57-64 and IC31
® 
vaccinated mice by the use of different injection routes 
The data from the screening for immunogenicity of different tumor-derived 
peptides revealed that not only TRP-2180-188, but SVN57-64 in combination with 
classical IC31® induced strong CD8+ T cell responses in central lymphoid organs. 
In the following experiment different injection routes as well as the nano 
formulation of IC31® were used to determine differences in the potential of IC31® to 
induce antigen-specific T cell immune responses in spleens and draining lymph 
nodes.  
The same experimental set up as described in 5.2. was used. Bernhard 
Roeder immunized C57BL/6 mice with SVN57-64 and IC31
® by the use of different 
injection routes (s.c., i.m., i.d. and i.p.) at three time points in a two-week interval 
(d0, 15 and 30). For control purpose, mice were immunized with antigen only.  
On day 15 after second and day 13 after third immunization, spleens and 
draining lymph nodes were harvested by Bernhard Roeder of the QC-IV 
department and single cell suspensions were prepared. IFN-  ELIspot assay and 
Intracellular Cytokine Staining were performed as described in Material and 
Methods. 
The ELIspot data indicate that after two immunizations of IC31® 
adjuvanted SVN57-64 did not induce a significant immune response in central 
lymphoid organs. On day 13 after third injection all different route vaccinated mice 
with antigen and IC31®, induced a weak T cell immune response in spleen cells 
(Figure 6A) in comparison to mice vaccinated with antigen alone. In the lymph 
nodes no antigen-specific CD8+ T cell response was observed (data not shown). 
Figure 6B compares IFN-γ production in spleen cells of SVN57-64 plus IC31 
vaccinated mice by the use of different injection routes over 43 day. S.c. injection 
induced the strongest T cell response compared with all other injection routes. The 
IFN-γ production from splenocytes in ELIspot was comparable with the 
Intracellular Cytokine Staining (data not shown). 
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 In summary, s.c. injections demonstrated to be the best route for the in 
vivo induction of splenic antigen-specific T cell responses. In following 
experiments these results were not reproducible and therefore SVN19-28 was used 
as Survivin derived peptide for further analysis. 
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Figure 6. IFN-  ELISpot analysis of CD8
+
 T cell responses upon immunization with SVN57-64 
and IC31
®
 in spleens. C57BL/6 mice were immunized on day 0, day 15 and day 30, s.c. in the tail 
base (100µl), i.m. (50µl/hind limb), i.d. (2x50µl, tail base) and i.p. (100µl) with SVN57-64 
(60µg/mouse) plus IC31
®
 nano (a mixture of 100nmole KLK and 4nmole ODN1a in 2.5mM Tris 
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buffer). For control purpose, mice were injected with antigen only. (A) Spleens were harvested on 
day 13 after third injection. Cells from each group were plated in triplicates at 1x10
6
 cells/well for 
spleens and at 5x10
5
 cells/well for lymph nodes and ex vivo restimulated with the relevant antigen 
(SVN57-64; 1µg/ml; purple) and with an irrelevant antigen (SVN19-28; 1µg/ml; green). Medium was 
used as negative control. IFN-  producing in spleen and draining lymph node cells was determined 
24 hours after restimulation in an ELIspot assay.  The results are shown as number of spot forming 
cells (SFC)/1x10
6
 total cells ± SD. (B) IFN-γ production on ELIspot  in spleen cells was determined 
over 43 days. The results are shown as the number of spot forming cells (SFC)/1x10
6
 total cells ± 
SD. The arrows indicate immunization time points.  
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5.4. Determination of systemic CD8+ T cell immune responses 
in central lymphoid organs and lungs induced by tumor-
derived peptides adjuvanted with IC31® upon intradermal 
and intranasal route vaccination 
Previous studies showed that by the use of intranasal and intradermal 
administration, vaccines elicit strong antigen-specific mucosal and systemic 
antigen-specific TH1 and/or TH2 immune responses (4, 43). 
Therefore, the focus of this study was to determine and characterize the 
efficiency of IC31® nano in improving the induction of a CD8+ T cell immune 
response as systemic and mucosal adjuvant against specific tumor-derived 
peptides, like TRP-2180-188 and SVN19-18 upon intradermal and intranasal 
application. 
An experimental setup with three immunizations in bi-weekly intervals was 
used.  C57BL/6 mice were intrademally (tail base) and intranasally immunized with 
antigen plus IC31®, performed by Bernhard Roeder of the QC-IV department. For 
control purpose, mice were injected with antigen and IC31® only. For intranasal 
administration Isofluran was used as anesthesia. To exclude errors during 
intranasal administration, an adjuvant control group plus antigen was included. 
Cholera Toxin B Subunit (CTB) is a potent adjuvant, often inducing even non-
specific stimulation, and in combination with the antigen, it induced a potent 
immune response (7). 
As positive control for Flow cytometry analysis and FlowCytomixTM, 
Phorbol-12-myristate-13-acetete (PMA)/Ionomycin and Concanavalin A (ConA) 
were used. PMA is on the one hand a tumor promoter that activates Kinase C in 
the presence of a physiological intracellular concentration of calcium. Ionomycin 
raises the calcium concentration and stimulates in combination with PMA 
intracellular cytokine production (56). ConA is on the other hand a mitogen that is 
known to stimulate T cells (57). 
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5.4.1. Induction of TRP-2180-188 / IC31
® CD8+ T cell immune 
responses in spleens and draining lymph nodes by the use 
of intradermal and intranasal immunization 
 
To investigate a systemic CD8+ T cell response of adjuvanted TRP-2180-188 
vaccinated mice in vivo, C57BL/6 mice were immunized at three time points in a 
two week interval (day 0, 13 and 28) intradermally and intranasally by Bernhard 
Roeder of the QC-IV department. For control purpose, mice were injected with 
peptide and IC31® only. Due to the vaccine formulation aspects, the amount of 
IC31® used for the two injection routes differed as followed: 100/4 IC31® for 
intradermal immunization and 20/0.8 IC31® for intranasal administration. Spleens 
and draining lymph nodes were harvested by Bernhard Roeder on day 14 after 
second and third injection. Cell suspensions were prepared and IFN-  ELIspot, 
Intracellular Cytokine Staining, Granzyme B Staining and FlowCytomixTM were 
performed as described in Materials and Methods. 
By ELIspot assay IFN-γ production was evaluated in spleens (Figure 7A) 
and inguinal lymph nodes (Figure 7B) of TRP-2180-188 adjuvanted in IC31
® 
intrademally vaccinated mice over a period of 42 days. After the third injection a 
significant increase of CD8+ T cell immune response was determined by an 
increasing IFN-  production in central lymphoid organs. Intranasally administered 
groups did not elicit any T cell immune responses in spleen and broncheo-tracheal 
lymph node cells, except the adjuvant control group, antigen plus CTB (data not 
shown). 
Regarding to Intracellular Cytokine Staining (Figure 8A), a high increase of 
double positive cytokine producing CD8+ T cells in spleens (IFN- /IL-2, IFN- /TNF-
α and TNF-α/IL-2 expression) were observed in TRP-2180-188 plus IC31
® 
intradermal vaccinated mice on day 14 after third injection in comparison  to 
respective control groups. The cells were ex vivo restimulated with the relevant 
peptide TRP-2180-188 and the irrelevant peptide SVN19-28 as respective control.  
Table 1 summarizes the obtained percentage of double positive cytokine 
producing CD8+ T cells in spleens after third intradermal immunizations by Flow 
cytometry analysis.  
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A significant up-regulation of Granzyme B in spleens was observed upon 
third immunization in comparison to the control groups, antigen or IC31® only 
(Figure 8B). The cells were ex vivo restimulated with the relevant peptide TRP-
2180-188 and the irrelevant peptide SVN19-28 as respective control. These data 
reveal that TRP-2180-188 in combination with IC31
® significantly activated cytotoxic 
T cells in spleens after three intradermal immunizations.  
For cytokine production profiling, splenocytes were plated and ex vivo 
restimulated with ConA as positive control, complete medium as negative control, 
TRP-2180-188 as relevant peptide and SVN19-28 as irrelevant peptide. After 48 hours 
supernatants were taken and the cytokine production profile   was performed using 
a FlowCytomixTM kit as described in Materials and Methods.  
TRP-2180-188 adjuvanted in IC31
® vaccinated mice induced a significant 
high IFN-  expression and a slight increase in IL-2, IL-6, IL-10, TNF-α and GM-
CSF production after three intradermal immunizations (Table 2). IL-1α, IL-4, IL-5 
and IL-17were produced under the detection limit. The obtained IFN-  and TNF-α 
expression data confirm the results obtained with flow cytometry analysis. The 
intranasally immunized mice did not produce any of these ten cytokines, except 
the adjuvant control group, antigen plus CTB, which elicited IL-2, IL-6, IL-10, IL-17, 
GM-CSF, INF-  and TNF-α cytokine production (data not shown). 
In conclusion, the presented data indicate strong antigen-specific CD8+ T 
cell responses in central lymphoid organs upon third intradermal injection of TRP-
2180-188 adjuvanted in IC31
® vaccinated mice. 
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Figure 7. Analysis of IFN-  production in spleens and lymph nodes upon intrademal and 
intranasal immunization of TRP-2180-188 with IC31
® 
over 42 days by ELIspot assay. C57BL/6 
mice were immunized on day 0, day 13 and day 28 i.d. (2x50µl) and i.n. (40µl) immunized with 
TRP-2180-188 (60µg/mouse) plus IC31
®
 nano (a mixture of 100nmole KLK and 4nmole ODN1a in 
2.5mM Tris buffer). For i.n. control purpose mice were immunized with TRP-2180-188 (60µg/mouse) 
plus CTB (1µg/mouse; adjuvant control). (A) Spleens and (B) inguinal lymph nodes were harvested 
on day 14 after second and third immunization. Cells from each group were plated in triplicates at 
5x10
5
 cell/well for splenocytes and at 1x10
6
 cells/well for draining lymph nodes and were ex vivo 
restimulated with the relevant antigen (TRP-2180-188; 1µg/ml) and an irrelevant antigen (SVN19-28; 
1µg/ml). IFN-  producing in spleen and draining lymph node cells was determined 24 hours after 
restimulation in an ELIspot assay.  IFN-γ production is shown over a period of 42 days. The results 
are shown as number of spot forming cells (SFC)/1x10
6
 total cells ± SD. The arrows indicate the 
immunization time points. 
 
 
 
Table 1: Summary: Antigen in combination with IC31
®
 induced up-regulation of cytokine producing 
double positive CD8
+
 T cells following intradermal immunization and ex vivo restimulation (relevant 
antigen: TRP-2180-188 and irrelevant peptide: SVN19-28); numbers are shown as percentage of 
double-positive cells in comparison to the respective control groups. Data were obtained by Flow 
cytometry analysis. 
 
Stimuli Immunization IFN-γ/IL-2 IFN-γ/TNF-α TNF-α/IL-2 
 
  
Antigen + 
IC31
®
 0.9 0.9 0.9 
Relevant 
peptide TRP-2 180-188 Antigen 0.1 0.0 0.1 
 
  IC31 0.1 0.0 0.3 
 
  
Antigen + 
IC31
®
 0.1 0.0 0.2 
Irrelevant 
peptide SVN19-28 Antigen 0.1 0.0 0.1 
 
 IC31 0.1 0.0 0.2 
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Figure 8. Flow cytometry analysis of cytotoxic CD8
+
 T cells in spleen of TRP-2180-188 and 
IC31
®
. C57BL/6 mice were immunized on day 0, day 13 and day 28, i.d. (2x50µl) with TRP-2180-188 
(60µg/mouse) plus IC31
®
 nano (a mixture of 100nmole KLK and 4nmole ODN1a in 2.5mM Tris 
buffer). For control purpose, mice were injected with antigen and IC31
®
 only. Spleens were 
harvested on day 14 after third immunization. Cells of each group were plated in triplicates at 1x10
6
 
cells/well and ex vivo restimulated with the relevant antigen (TRP-2180-188; 1µg/ml; upper blots) and 
with an irrelevant antigen (SVN19-28; 1µg/ml; lower blots). (A) Intracellular Cytokine Staining was 
performed to evaluate the percentage of cytokine producing splenic double positive CD8
+
 T cells in 
mice i.d. vaccinated. (B) Number of Granzyme B producing CD8
+
 T cells in spleens of i.d. 
immunized mice were determined. Stained cells were gated on the CD8
+
 cells. 500.000 events per 
sample were acquired.   
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CYTOKINES STIMULI TRP-2180-188 TRP-2180-188 + IC31
®
 IC31
®
 
  ConA >27764,92 18280,66 19989,89 
IFN-  Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 2414,88 <d.l. 
  SVN19-28 <d.l. <d.l. <d.l. 
  ConA 224,95 228,1 218,74 
TNF-α Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 9,4 <d.l. 
  SVN19-28 <d.l. <d.l. 2,3 
  ConA 398,97 502,66 397,5 
GM-CSF Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 37,19 23,36 
  SVN19-28 <d.l. <d.l. 15,92 
  ConA 771,3 614,69 795,31 
IL-6 Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 114,77 <d.l. 
  SVN19-28 <d.l. <d.l. <d.l. 
  ConA 239,78 409,6 329,87 
IL-2 Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 119,17 <d.l. 
  SVN19-28 <d.l. <d.l. <d.l. 
  ConA >27764,92 18280,66 19989,89 
IL-10 Medium <d.l. <d.l. <d.l. 
  TRP-2180-188 <d.l. 2414,88 <d.l. 
  SVN19-28 <d.l. <d.l. <d.l. 
 
Table 2. FlowCytomix
TM
 cytokine profile of splenic lymphocytes after third intradermal 
immunizations of antigen plus IC31
®
. For control purpose, mice were injected with antigen or 
IC31
®
 only. Ex vivo restimulation for 48hrs (positive control: ConA; negative control: complete 
medium; relevant antigen: TRP-2180-188 (1µg/ml) and irrelevant antigen SVN19-28 (1µg/ml)); numbers 
are shown as pg/ml cytokine in the supernatants harvested. All other cytokines were below 
detection limit. (<d.I. = below detection limit).  
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5.4.2. FlowCytomixTM determination of specific CD8+ T cell 
immune responses in lungs of mice  intradermally and 
intranasally vaccinated with TRP-2180-188 and IC31
® 
adjuvanted. 
In parallel to IFN-  ELIspot assay and Flow cytometry analysis, cell 
suspensions of lungs without the use of Lymphocyte Separation Medium, was 
prepared as described in Materials and Methods. To use only CD8+ T cells for 
further analysis, cell suspensions were sorted for CD8+ T cells by the use of 
magnetic cell sorting (MACS) as described in Material and Methods. The purity of 
CD8+ T cells was on an average of 98% as determined by Flow cytometry analysis 
(data not shown). 
Cells were plated for FlowCytomixTM. To present antigen to purified CD8+ 
T cells, Antigen Presenting Cells (APCs) from spleens of 3 naïve C57BL/6 mice 
were added (1:2). Cells were 48 hours restimulated with ConA as positive control, 
complete medium as negative control, TRP-2180-188 as relevant peptide and SVN19-
28 as irrelevant peptide.  After two days the supernatants were taken and 
FlowCytomixTM was performed as described in Materials and Methods.  
The obtained results reveal that after the second intradermal immunization 
of TRP-2180-188 and IC31
®, IFN-  was upregulated by CD8+ T cells in lungs in 
comparison to a slight production of TNF-α, IL-6, IL-10, IL-2 and GM-CSF. A 
moderate increase of all these mentioned cytokines was determined after the third 
immunization (Table 3). IL-4, IL-5, IL-17 and IL-1α were produced under detection 
limit in the lungs after the third immunization of antigen in combination with IC31®. 
The intranasally vaccinated mice did not induce any production of these 
ten cytokines, except for the adjuvant control group, antigen plus CTB (data not 
shown). 
In conclusion, the data reveal the induction of CD8+ T response in central 
lymphoid organs and at mucosal sites of TRP-2180-188 and IC31
® vaccinated mice. 
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CYTOKINES STIMULI TRP-2180-188 TRP-2180-188 + IC31
®
 IC31
®
 
  ConA <d.l. <d.l. >10403,84 
IFN-  Medium 41,56 37,79 47,25 
  TRP-2180-188 301,02 >23880,41 249,93 
  SVN19-28 196,59 67,46 71,51 
  ConA 139,48 115,83 31,94 
TNF-α Medium 14,54 <d.l. 2,3 
  TRP-2180-188 24,8 87,74 4,14 
  SVN19-28 9,4 <d.l. <d.l. 
  ConA 424,82 718,02 168,8 
GM-CSF Medium 46,16 26,5 57,89 
  TRP-2180-188 48,24 296,93 54,15 
  SVN19-28 25,75 25,75 28,6 
  ConA 1117,72 1496,57 1351,4 
IL-6 Medium 109,9 350,3 697,47 
  TRP-2180-188 185,97 851,72 722,33 
  SVN19-28 115,99 399,14 725,13 
  ConA 5597,76 1845,87 361,11 
IL-2 Medium <d.l. <d.l. 19,69 
  TRP-2180-188 3,52 151,02 3,52 
  SVN19-28 <d.l. <d.l. 17,56 
  ConA <d.l. <d.l. <d.l. 
IL-10 Medium <d.l. <d.l. 88,69 
  TRP-2180-188 6,66 154,15 25,62 
  SVN19-28 <d.l. 18,13 24,07 
 
Table 3. FlowCytomix
TM
 cytokine profile of mucosal lymphocytes after third intradermal 
immunizations of antigen plus IC31
®
. For control purpose, mice were injected with antigen or 
IC31
®
 only. Ex vivo restimulation for 48hrs (positive control: ConA; negative control: complete 
medium; relevant antigen: TRP-2180-188 (1µg/ml) and irrelevant antigen SVN19-28 (1µg/ml)); numbers 
are shown as pg/ml cytokine in the supernatants harvested. All other cytokines were below 
detection limit. (<d.I. = below detection limit).  
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5.4.3. Determination of cellular immune response of SVN19-28 with 
IC31® intradermally and intranasally vaccinated mice by 
using IFN-  ELIspot assay 
A reasonable argument for changing the Survivn derived peptide, SVN57-64 
to SVN19-28, was that only in one experiment the induction of an antigen-specific 
CD8+ T cell immune response in combination with IC31® nano was observed after 
third immunization. These data were never reproducible and in following 
immunization studies SVN57-64 and the adjuvant failed in eliciting an immune 
response. 
However, to determine systemic antigen-specific CD8+ T cell responses 
with the nano formulation of IC31® in central lymphoid organs upon intradermally 
and intranasally vaccination, C57BL/6 mice were at three time points in a bi-
weekly interval (day 0, 13 and 29) intradermally and intranasally immunized with 
SVN19-28 and IC31
® by Bernhard Roeder of the QC-IV department. For control 
purpose, mice were injected with peptide and adjuvant only. Due to the vaccine 
formulation aspects, the amount of IC31® used for the two injection routes differed 
as followed: 100/4 IC31® for intradermal immunization and 20/0.8 IC31® for 
intranasal administration. Spleens and draining lymph nodes were harvested on 
day 14 after second and day 13 after third injection by Bernhard Roeder. Cell 
suspensions were prepared and IFN-  ELIspot, Granzyme B Staining and 
FlowCytomixTM were performed as described in Materials and Methods. 
Figure 9 shows IFN-γ production in spleens and inguinal lymph nodes of 
SVN19-28 adjuvanted with IC31
® vaccinated mice over 42 days obtained by ELIspot 
assay. After the third injection, a moderate increase of CD8+ T cell response was 
elicited in spleens (Figure 9A) and lymph nodes (Figure 9B) by IFN-  expression. 
Intranasal administration did not induce any immune responses central lymphoid 
organs, except in the control group, antigen plus CTB, where again a weak 
immune response was determined (data not shown). 
 Regarding Granzyme B Staining a slight Granzyme B production was 
observed on day 13 after third intradermal immunizations in spleen cells (Figure 
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10). These data reveal that SVN19-28 in combination with IC31
® activated cytotoxic 
T cells (CTLs) in spleens after three interdermal immunizations.  
In summary, the obtained data indicate that SVN19-28 in combination with 
IC31® indicate an induction of a systemic CTLs in central lymphoid organs after 
third intradermal immunizations, but the CD8+ T cells were not polyfuncional, 
because only IFN-  production was determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Analysis of IFN-  production in spleens and lymph nodes after intradermal 
immunization of SVN19-28 and IC31
®
 by IFN-  ELIspot assay. C57BL/6 mice were immunized on 
day 0, day 13 and day 28, i.d. (2x50µl) with SVN19-28 (60µg/mouse) plus IC31
®
 nano (a mixture of 
100nmole KLK and 4nmole ODN1a in 2.5mM Tris buffer). (A) Spleens and (B) lymph nodes were 
harvested on day 14 after second and day 13 after third immunization. Cells from each group were 
plated in triplicated at 5x10
5
 cells/well for spleens and at 1x10
6
 cells/well for lymph nodes and were 
ex vivo restimulated with the relevant antigen (SVN19-28; 1µg/ml) and with an irrelevant antigen 
(TRP-2180-188; 1µg/ml). Medium was used as negative control. IFN-  production in spleen and lymph 
node cells was determined 24 hours after restimulation in an ELIspot assay. The results are shown 
as number of spot forming cells (SFC)/1x10
6
 total cells ± SD. 
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Figure 10. Flow cytometry analysis of Granzyme B producing cytotoxic CD8
+
 T cells in 
spleen of SVN19-28 adjuvanted in IC31
® 
intradermal vaccinated
 
mice. C57BL/6 mice were 
immunized on day 0, day 13 and day 28 i.d. (2x50µl) with SVN19-28 (60µg/mouse) plus IC31
®
 nano 
(a mixture of 100nmole KLK and 4nmole ODN1a in 2.5mM Tris buffer). For control purpose, mice 
were injected with antigen and IC31
®
 only. Spleens were harvested on day 13 after third 
immunization. Cells were plated in triplicates at 1x10
6
 cells/well and ex vivo restimulated with the 
relevant antigen (SVN19-28; 1µg/ml) and with an irrelevant antigen (TRP-2180-188; 1µg/ml). Number of 
Granzyme B producing CD8
+
 T cells in spleens of i.d. immunized mice were determined. Stained 
cells were gated on the CD8
+
 cells. 500.000 events per sample were acquired.   
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5.4.4. Determination of cytokine production in lungs and spleens 
of SVN19-28 and IC31
® intradermally and intranasally 
vaccinated mice by using FlowCytomixTM 
 
In parallel to IFN-γ ELIspot and Flow cytometry analysis, FlowCytomixTM 
was performed to characterize antigen-specific systemic CD8+ T cell responses by 
cytokine production in spleens as well as at mucosal sites. 
 Single cell suspensions from both organs were prepared as described in 
Materials and Methods. Additionally, lungs were purified without the use of LSM. 
The lung cells were sorted for CD8+ T cells by the use of MACS sort as described 
in Materials and Methods. The purity of CD8+ T cells was on an average of 99% as 
determined by Flow cytometry analysis (data not shown). 
 Spleen and purified CD8+ T cells from lungs were plated for 
FlowCytomixTM. Cells were ex vivo restimulated with ConA as positive control, 
complete medium as negative control, SVN 19-28 as relevant antigen and TRP-2180-
188 as irrelevant antigen. After 48 hours supernatants were taken and 
FlowCytomixTM was performed as described in Materials and Methods.  
 The obtained data reveal high IFN-γ production in spleens of SVN19-28 
adjuvanted in IC31® vaccinated mice and a slight increase of IL-6 and IL-10 upon 
intradermal immunization (Table 4). IL-4, IL-5, IL-17, IL-1α, GM-CSF, TNF-α and 
IL-2 were produced under detection limit. 
 At mucosal sites of intradermally SVN19-28 and IC31
® vaccinated mice high 
amounts of IFN-γ (Table 5) were produced. IL-4, IL-5, IL-17, IL-1α, GM-CSF, TNF-
α, IL-6, IL-10 and IL-2 were expressed under detection limit. 
 Intranasally vaccinated mice did not induce any production of these 
cytokines in spleens and lungs, except the adjuvant control group, antigen plus 
CTB (data not shown). 
 In conclusion, the obtained results indicate the highly efficiency of IC31® in 
inducing a systemic antigen specific immune response in central lymphoid organs 
and lungs. But these data suggest that the elicited CD8+ T cells were not 
polyfunctional, because only IFN-  and any other cytokine was evaluated by 
FlowCytomixTM. 
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CYTOKINES STIMULI SVN19-28 SVN19-28 + IC31
®
 IC31
®
 
  ConA 12208,99 13972,9 13814,37 
IFN-  Medium <d.l.  <d.l.  <d.l.  
  SVN19-28 <d.l.  326,35 <d.l.  
  TRP-2180-188 <d.l.  <d.l.  <d.l.  
 
Table 4. FlowCytomix
TM
 cytokine profile of splenic lymphocytes after third intradermal 
immunizations of antigen plus IC31
®
. For control purpose, mice were injected with antigen and 
IC31
®
 only. Ex vivo restimulation for 48hrs (positive control: ConA; negative control: complete 
medium; relevant antigen: SVN19-28 (1µg/ml) and irrelevant antigen TRP-2180-188  (1µg/ml)); numbers 
are shown as pg/ml cytokine in the supernatants harvested. All other cytokines were below 
detection limit. (<d.I. = below detection limit).  
 
 
CYTOKINES STIMULI SVN19-28 SVN19-28 + IC31
®
 IC31
®
 
  ConA  >26298,45  15689,68 18337,55  
IFN-  Medium <d.l. 3,52 <d.l. 
  SVN19-28 445,09 1195,11 71,51 
  TRP-2180-188 <d.l. 112,19 <d.l. 
 
Table 5. FlowCytomix
TM
 cytokine profile of mucosal lymphocytes after third intradermal 
immunizations of antigen plus IC31
®
. For control purpose, mice were injected with antigen and 
IC31
®
 only. Ex vivo restimulation for 48hrs (positive control: ConA; negative control: complete 
medium; relevant antigen: SVN19-28 (1µg/ml) and irrelevant antigen TRP-2180-188  (1µg/ml)); numbers 
are shown as pg/ml cytokine in the supernatants harvested. All other cytokines were below 
detection limit. (<d.I. = below detection limit).  
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5.5. Determination  of long lasting immune responses in 
spleens and lymph node by using IFN-  ELIspot assay 
 
The last question arising from these results was, if the observed specific 
antigen immune responses in combination with the nano formulation of IC31® 
maintain a long lasting immune response. To investigate this, the CD8+ T cell 
responses of antigen plus adjuvant vaccinated mice were analyzed at a later time 
point according to three immunization. Due to the long lasting aspect, the effect of 
a CD4+ Helper peptide, Hepatitis B Core (HBc or HBVc) peptide, was included. 
 For this purpose, an experiment was set up, again consisting of three 
immunization time points (day 0, 14 and 28). C57BL/6 mice were injected bi-
weekly subcutaneously, intradermally and intranasally by Bernhard Roeder, with 
TRP-2180-188 in combination with IC31
® or TRP-2180-188 plus IC31
® and inclusive 
HBc, to determine differences in the CD8+ T cell responses within spleens and 
draining lymph nodes. For control purpose, mice were immunized with antigen and 
IC31® only, as well as with peptide plus HBc. Spleens and draining lymph nodes 
were harvested on day 11 after second, and day 12 and 70 after third injection by 
Berhard Roeder. IFN-  ELIspot assay and Intracellular Cytokine Staining were 
performed as described in Materials and Methods. The number of spot forming 
cells in the IFN-  ELIspot assay was in the following described experiment lower 
than in all other described experiments, because the batches of TRP-2180-188 
peptide were mixed. 
  The IFN-  ELIspot data indicate that after three immunizations the 
observed CD8+ T cell responses in draining lymph nodes (Figure 11A) and 
spleens (Figure 11) increased in mice immunized s.c. and i.d. with TRP-2180-188 
plus IC31®  as well as with TRP-2180-188 plus IC31
®  and HBc, in comparison to 
results after two injections (data not shown) and respective control groups. The 
intranasally administered mice did not induce any IFN-  production at all time 
points.  
 The obtained results indicate that the Helper peptide (HBc) induced not a 
significant higher antigen-specific immune response in central lymphoid organs in 
combination with the results from mice, vaccinated with TRP-2180-188 and IC31
®. 
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The results of IFN-  ELIspot assay were comparable with the Intracellular Cytokine 
Staining (data not shown).  
  Figure 12 focus on intranasal and intradermal vaccination and indicate 
significant CD8+ T cell responses in spleens (Figure 12A and C) and draining 
lymph nodes (Figure 12B+D) of TRP-2180-188 plus IC31
® (Figure 12A+B) as well as 
TRP-2180-188 plus IC31
®  and HBc  (Figure 12C+D) immunized mice over 98 days. 
These data reveal that long lasting memory CD8+ T cells were activated in spleens 
and inguinal lymph nodes on day 70 after third intradermally vaccination of TRP-
2180-188 in combination with IC31
® . The CD4+ Helper peptide did not induce any 
significant increase of CD8+ T cell responses in splenocytes and lymph node cells 
over a longer period of time. 
  The intranasal administered mice did not elicit any T cell response in 
primary lymphoid organs at any time point. The ELIspot data matched with the 
results of Flow cytometry analysis.   
In conclusion, the obtained data indicate that the potency of IC31® nano in 
inducing a strong TRP-2180-188 specific CD8
+ T cell responses in central lymphoid 
organs upon third intradermal immunizations. The vaccination of antigen plus 
adjuvant could elicit the formation of a depot that in terms is necessary for the 
induction of a long lasting immune response. The CD4+ Helper peptide had no 
significant increasing effect on induction of a CD8+ T cell response in primary 
lymphoid organs. 
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Figure 11. Analysis of antigen-specific CD8
+
 T cell immune response upon 3
rd
 immunization 
by IFN-  ELIspot assay. C57BL/6 mice were immunized on day 0, day 14 and day 28, s.c. (100µl, 
tail base), i.d. (2x50µl) and i.n. (40µl) with TRP-2180-188 (60µg/mouse) plus IC31
®
 nano (a mixture of 
100nmole KLK and 4nmole ODN1a in 2.5mM Tris buffer) as well as the CD4
+
 helper peptide HBc. 
For control purpose, mice were injected with antigen and IC31
®
 only. (A) Draining lymph nodes and 
(B) spleens were harvested on day 12 after third immunization.  Cells of each group were plated in 
triplicates at 5x10
5
 cells/well for spleens and at 1x10
6
 cells/well for lymph nodes and ex vivo 
restimulated with the relevant antigen (TRP-2180-188; 1µg/ml; red), with an irrelevant antigen (SVN19-
28; 1µg/ml; green) and CD4
+
 helper peptide (HBc; 1µg/ml; blue). Medium was used as negative 
control. IFN-  production in spleen and lymph node cells was determined 24 hours after 
restimulation in an ELIspot assay. (C) The same procedure was done with spleens on d70 after 
third immunization. The results are shown as number of spot forming cells (SFC)/1x10
6
 total cells ± 
SD. 
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Figure 12. Analysis of IFN-γ production after intradermal and intranasal vaccination in 
spleens and draining lymph nodes over 98 days. C57BL/6 mice were immunized on day 14 and 
day 28, i.d. (2x50µl) and i.n. (40µl) with TRP-2180-188 (60µg/mouse) plus IC31
®
 nano (a mixture of 
100nmole KLK and 4nmole ODN1a in 2.5mM Tris buffer) as well as the CD4
+
 helper peptide 
HBc.intradermally. IFN-  production in spleen (A+C) and lymph node (B+D) cells was determined 
24 hours after restimulation in an ELIspot assay. (A) and (B) shows IFN-γproduction after 
immunization of TRP-2180-188 adjuvanted with IC31
®
. (C) and (D) indicate IFN-γ production in mice, 
vaccinated with TRP-2180-188, HBc as well as IC31
®
.
 
The results are shown as number of spot 
forming cells (SFC)/1x10
6
 total cells ± SD. Arrows indicate the immunization time points. 
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6.   DISCUSSION 
 Recent identifications on the property of IC31® in improving an antigen-
specific CD8+ T cell immune response prompted us to further investigate the 
potential effects of the novel bi-component adjuvant in inducing a CTL response 
against cancer. Therefore, distinct TRP-2 and Survivin derived peptides, which are 
important tumor-associated antigens with restricted expression, are excellent 
candidates for antitumor vaccines (10, 34, 37). 
 Six promising clinical relevant peptides, namely SVN18-27, SVN19-28, 
SVN57-64, SVN82-89, SVN53-67 and TRP-2180-188, were selected on the basis of 
eliciting CTL responses. A screening for detecting immunogenicity of the peptides 
as well as the adjuvantive effect of classical IC31® in terms of improving the 
induction of antigen-specific CD8+ T cell immune responses was setup. Previous 
studies showed the great potency of classical IC31® in inducing potent TH1 T cell 
immune responses and cytotoxic T cell activity when co-injected with 
immunogenic peptides or proteins (18). The data obtained during this study 
supported the notion that IC31® strongly enhanced the immunogenicity of SVN19-
28, SVN57-64 and TRP-2180-188 characterized by the induction of type 1 cellular 
immune responses evaluated by IFN-  production in spleens and lymph nodes. 
Altogether TRP-2180-188, SVN57-64 and SVN19-28 seemed to be preferable vaccine 
candidates. 
Further, SVN57-64 and TRP-2180-188 as well as different immunization routes (s.c., 
i.d., i.m. and i.p.) were used to determine differences on the immunostimulatory 
effect of IC31® nano. This study was designed to get more information on the 
adjuvantive potency of IC31® nano in terms of enhancing the induction of antigen-
specific CD8+ T cell responses. The advantages of the development of 
nanoparticulated adjuvantive systems are the improved uptake of antigens by 
APCs and therefore the promotion of an effective immune response as well as the 
use for different beneficial therapeutic route vaccinations (19, 20). The obtained 
data of this immunization studies revealed the high efficiency of IC31® nano in 
eliciting an antigen-specific CD8+ T cell immune response by IFN-  production in 
central lymphoid organs. In general, s.c. and i.d. route vaccination were more 
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efficient in inducing higher antigen-specific CD8+ T cell responses upon co-
injection of the antigens and the adjuvant than other immunization routes (i.p. and 
i.m.). These efficiency derives from the high densities of Langerhans cells (LCs) 
that are present in the skin and enhances as specific DCs the induction of an 
immune response (58).  
 In more detail, IC31® supported the induction of a TRP-2180-188 
(SVYDFFVWL) peptide-specific CD8+ T cell immune response in C57BL/6 mice. 
IFN-  production increased in spleens and lymph nodes after the third vaccination 
and was twice as high as after second immunization except i.m. route vaccinated 
animals. The increased immune response may be explained by the fact that after 
the second immunization a number of peptide-specific T cells were already primed 
by IC31® adjuvanted TRP-2180-188 that strongly were enhanced and largely 
expanded once again after the third immunization of the vaccine. The results of 
the i.m. immunized animals revealed that the use of mixed immunization routes 
(i.m. and i.d.) affected IFN-  production in lymph nodes neglecting the induction of 
CD8+ T cells.  
However, the presented data showed a limited efficiency of IC31® nano in 
terms of inducing SVN57-64 specific IFN-  production in central lymphoid organs. 
Three immunizations were necessary to elicit a CD8+ T cell immune response. 
The fact that immunization studies in C57BL/6 mice assessed that SVN57-64 was 
not sufficiently immunogenic and failed to elicit immune responses in combination 
with IC31®, SVN19-28 was used for further immunization studies. SVN19-28 is a 
Survivin derived peptide which showed in the screening a strong immune 
response in terms of IFN-γ production in combination with the adjuvant. The 
lacking of CD8+ T cell responses towards the adjuvanted CD8+ epitope, SVN57-64 
(CFFCFKEL) could be explained by two cysteines in the amino acid sequence that 
may have induced the formation of a disulfide bond in contact with oxygen. 
Consequently this could lead through an conformational change of the peptide 
(59). A suboptimal binding of the peptide through IC31® could influence the antigen 
presentation to APCs as well as induction of antigen-specific CD8+ T cell immune 
responses. 
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Previous studies showed that by the use of intranasal and intradermal 
administration, vaccines elicit strong antigen-specific mucosal and systemic 
antigen-specific TH1 and/or TH2 immune responses (4, 43). Therefore the 
efficiency of IC31® in supporting induction of tumor-derived peptide specific 
immune responses as mucosal and systemic adjuvant was evaluated by 
immunization studies of TRP-2180-188 or SVN19-28 adjuvanted in co-injected with 
IC31® elicited strong systemic CD8+ T cell immune response in central lymphoid 
organs and at mucosal sites upon intradermal vaccination. These data imply the 
activation of specific murine and human DCs in the skin, (Langerhans cells, LCs) 
that express different TLRs, especially TLR9 which play an important role to guide 
the choice of the TLR9 agonist IC31® (10, 50, 51). LCs aim the induction of CTL 
and are essential for anti-tumor immunity in vivo and therefore intradermal route 
vaccination is a promising immunization route candidate (52).  
Further, three i.d. immunizations of the adjuvanted peptides were 
necessary to get the best antigen-specific immune response. The fact that the 
highest immune response was achieved upon three vaccinations was already 
observed in previous studies (personal communication Karin Riedl). 
 In more detail, the data obtained from TRP-2180-188 in combination with 
IC31® vaccinate mice, revealed the induction of a high systemic CD8+ T cell 
response in terms of IFN-  production in central lymphoid organs and at mucosal 
sites when delivered via the intradermal route. The induction of a strong systemic 
CD8+ T cell immune response was further supported by FlowCytomixTM data 
where upon in vitro restimulation of spleen and lung cells, which were derived from 
C57BL/6 mice on day 14 after third i.d. immunization indicated beside the 
improved IFN-  production, a substantial increase of IL-2, IL-6, IL-10, GM-CSF and 
TNF-α even more in the group immunized with IC31® adjuvanted TRP-2180-188. 
Adjuvant- and peptide alone vaccinated mice did not show these highly cytokine 
production. Regarding specific cytokine expression, such as IL-2 that was 
characterized as a potent T cell growth factor, provide in combination with the 
proinflammatory IFN-  and TNF-α, a set of cytokines that defines a vaccine-elicited 
cytolytic T cell response against specific antigens (21, 23) Concerning the 
pronounced production of IL-6 and IL-10 in cancer, various studies demonstrated 
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the importance of both cytokines, beside others to regulate tumor growth or 
antitumor immune responses. IL-6 on the one hand is involved in enhancing 
immunological responses while IL-10 influence the magnitude of CD8+ T cell 
responses by eliciting regulatory T cells (23, 60). Further, GM-CSF upregulation in 
spleens and lungs could be explained by previous data that imply the involvement 
in immunological response enhancement as well as an effect on the maturation of 
LCs (55).   
 Additionally, the induction of an antigen specific CTL response was further 
supported by Granzyme B production in spleens of intradermal route vaccination 
C57BL/6 mice. These data indicated the potency of IC31® in strongly enhancing 
antigen-specific CTLs which deliver cytotoxic granules to the surface of the target 
cell and promote rapid and efficient cell death (27). Altogether, these data 
supported the TRP-2180-188 specific cytotoxic CD8
+ T cell immune response-
inducing effect of IC31®. 
 Regarding the data of the Survivin derived peptide, SVN19-28 in 
combination with the adjuvant, revealed the induction of a high systemic CD8+ T 
cell response evaluated by IFN-  production in central lymphoid organs and at 
mucosal sites following intradermal application. The results indicated that together 
with IFN-  production IC31® improved the generation of a SVN19-28-specific CTL 
response obtained by the upregulation of Granzyme B in spleen cells of C57BL/6 
mice. The data observed in this study demonstrate the enhancement of a systemic 
immune response by IFN-  production in SVN19-28 adjuvanted in IC31
® animals. 
Nevertheless, the CD8+ T cells produced were not polyfunctional as any other 
cytokine than IFN-  were detected by FlowCytomixTM and Flow cytometry analysis. 
Altogether these data revealed the SVN19-28-specific CTL response-inducing effect 
of IC31® upon intradermal administration.  
Interestingly, both peptides adjuvanted in IC31® were not sufficiently 
immunogenic and failed in eliciting an antigen specific systemic CD8+ T cell 
immune response in combination with IC31® in central lymphoid organs as well as 
at mucosal sites when delivered via intranasal route. Intranasal immunization 
studies of the tumor-derived peptides in combination with CTB as mucosal 
adjuvant led to the activation of an antigen-specific TH1 immune response 
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obtained by IFN-  production. CTB has the capacity to act as efficient adjuvant and 
carrier for antigen-specific cytotoxic T lymphocyte (CTL) induction and shows 
adjuvantiv effects via the nasal immunization route. Therefore it was used as an 
additional adjuvant control during this study (7, 8). 
Previous data showed the adjuvantive effect of IC31® in local as well as 
systemic compartments following intranasal application in combination with the 
Chlamydia pneumoniae (Cpn) protein, CopN (unpublished data of Dominic 
Aschenbrenner). An explanation for the lacking tumor-derived peptide specific 
CD8+ T cell immune response upon intranasal administration could be a 
suboptimal binding of the peptides through IC31®.  The single component KLK 
usually entrap the antigen and ODN1a and therefore facilitates an efficient uptake 
in association of antigen to APCs  and formation of a vaccine depot at the injection 
site (18). It could be that the antigen is weakly bound to the bi-component adjuvant 
and not encapsulated. Consequently, the adjuvantive effect of IC31® may not 
support the induction of an antigen-specific CD8+ T cell immune response and 
additionally the adjuvant may be unable to form a depot at the injection site.  
An alternative explanation for failing the induction of a peptide specific 
immune response upon intranasal route vaccination could be that another delivery 
system, such as liposomes are necessary to deliver the antigen instead of the 
cationic peptide KLK. Studies reported that liposomes in complex with another 
TLR9 agonist, namely CpG greatly enhanced immune responses after intranasal 
administration and therefore it could be used for further intranasal immunization 
studies in combination with ODN1a and tumor-derived peptides (61).  
Altogether these data revealed that intranasal application of IC31® did not 
induce any antigen-specific CTL response and it seems that IC31® in comparison 
to CTB is not a promising mucosal adjuvant in enhancing a CD8+ T cell immune 
response against tumor-derived peptides.  
 The last question which arose was if IC31® nano supported the generation 
of a long lasting TRP-2180-188 specific immune response and, whether if there is 
any difference in regard of adding a CD4+ Helper peptide, called HBc. In brief, we 
tested the ability of the adjuvant and the peptide, in a three injections protocol 
were able to induce a long lasting immune response on day 70 after the third 
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immunization. The data obtained during this study revealed that IC31® had the 
potency to induce a significant number of IFN-  producing memory cells in spleens 
and lymph nodes of C57BL/6 mice upon intradermal and subcutaneous 
application. HBc did not improved the generation of memory cells by activating 
CD4+ T cells. The data for the sustained long lasting CD8+ T cell response could 
be explained by the fact that the immunostimulatory component KLK of IC31® has 
the efficiency to form a depot at the injection site and therefore control a sustained 
long-term antigen and adjuvant release (15). 
In summary, the encouraging results obtained for distinct tumor-derived 
peptides such as adjuvanted SVN19-28 and TRP-2180-188 revealed that both peptides 
are promising vaccine candidates. Furthermore, these data demonstrate the high 
potency of IC31® nano in supporting the induction of a long lasting systemic CD8+ 
T cell immune response as systemic adjuvant in central lymphoid organs and at 
mucosal sites. Intradermal route vaccination and IC31® as systemic adjuvant 
showed efficacy in inducing significant tumor-derived peptide specific immune 
responses without eliciting any toxic effects. Intranasal application and IC31® as 
mucosal adjuvant implicated any induction of antigen specific immune responses 
against tumor-derived peptides. 
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7.   MATERIALS AND METHODS 
7.1.   Materials 
7.1.1.  Reagents 
Aqua Distillate   Ampuwa 
Biotinylated anti-mouse IFN-  developing antibody BD PharmingenTM 
(0.5mg/ml stock conc.) 
Biotinylated anti-mouse IL-4 developing antibody BD PharmingenTM 
(0.5mg/ml stock conc.) 
BSA PAA- Laboratories 
Calcium Ionophore  Sigma (stock 7.5x10-5M) 
CD4 (L3T4) microbeads, mouse Miltenyi Biotec (10µl/107 
cells working conc.) 
ConA Sigma  
 (stock conc. 10mg/ml) 
Cytoperm/Cytofix BD PharmingenTM 
DAB Sigma 
DMEM PAA-Laboratories  
DMSO Applichem 
Fc (anti-mouse CD16/31 blocks Fc binding) BD PharmingenTM  
Fetal Bovine Serum (FBS) PAA-Laboratories  
Gentamicin PAA-Laboratories 
Golgi-Plug BD PharmingenTM  
30% H2O2 Sigma – Aldrich 
L-Glutamin PAA-Laboratories 
LSM PAA-Laboratories 
β-Mercaptoethanol GIBCO 
Mouse Th1/Th2 10plex Kit (Flow Cytomix) eBioscience 
NaCl (0.9%) B. Braun 
NaN3 Sigma 
NiCl2 Sigma 
Non-Essential amino acids PAA-Laboratories 
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Pan T Cell isolation kit Miltenyi Biotec  
Paraformaldehyde Sigma 
1x PBS PAA-Laboratories  
10x PBS GIBCO 
Perm/Wash (10x) BD PharmingenTM 
Purified rat anti-mouse IFN-  coating antibody BD PharmingenTM 
(0.5mg/ml stock conc.) 
Purified rat anti-mouse IL-4 coating antibody  BD PharmingenTM 
(0.5mg/ml stock conc.) 
Red Blood Cell Lysis Buffer  Sigma 
SA-HPO  Roche 
Sodium Pyruvate  PAA-Laboratories 
Trypan Blue (0.4%)  GIBCO 
Tween 20  Sigma-Aldrich 
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7.1.2.  Labeled antibodies for Flow Cytometry 
Table 6. Flow cytometry antibodies used for Flow cytometry analysis 
Antigen 
specifity 
Clone Isotype Fluorochrome Stock 
conc. 
mg/ml 
Working 
conc. 
µg/1x10e6 
cells 
Source 
7AAD   PerCP  1 eBio* 
CD4 RM4-5 rIgG2a 
AF488 
FITC 0.5 1 BD** 
CD8a 
(Ly-2) 
53-6.7 rat 
IgG2a 
Per-CP 0.2 2 BD 
CD8a 
(Ly-2) 
53-6.7 rat 
IgG2a 
APC 0.2 1 BD 
CD8a 
(Ly-2) 
53-6.7 rat 
IgG1 
PE 0.2 1 BD 
IFN-  XMG1.2 rat 
IgG1 
AF488 0.2 2 BD 
IL-2  rat 
IgG2b 
PE 0.2 2 BD 
TNF-α  rat 
IgG1 
APC 0.2 2 BD 
Granzyme B  rat 
IgG2b 
PE 0.2 1 eBio 
rat IgG1   PE 0.2 2 BD 
rat IgG2a   PerCP 0.2 2 BD 
rat IgG2a eBR2a  AF488 0.2 1 eBio 
rat IgG2a   APC 0.2 1 BD 
rIgG2b   PE 0.2 2 BD 
rat IgG2b eB149/10H5  PE 0.2 2 eBio 
 
*eBio: eBioscience 
**BD: Becton-Dickinson Pharmingen TM 
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7.1.3.  Media 
 For the isolation and in vitro incubation of splenocytes, lymph node or lung 
cells, complete medium was used. Complete medium consisted of DMEM, 5% 
FBS, 5ml sodium pyruvate, 5ml L-glutamine, 5ml non essential amino acids and 
additional 500 µl β-mercaptoethanol. 
For Flow cytometry analysis complete medium without 5% FBS was used. 
 
 
7.1.4. Mice 
Female C57BL/6 mice (H2b) were procured from Charles River 
laboratories (Germany) at an age of 6-8 weeks. All animal work was performed 
according to Austrian law. 
 
 
7.1.5. Adjuvant 
IC31® is a mixture of synthetic cationic poly-amino acid containing lysine 
and leucine [KLKL5KLK – (COOH)] and ODN1a (phosphodiester backbone ODN, 
oligo-(dIdC)13) which were purchased from Bachem (KLK) and Transgenomic 
(ODN1a). The single components of IC31® (nano) were mixed in 2.5mM Tris (pH = 
7) at a molar ratio of 2000nmol KLK / 80nmol ODN1a and was stored at room 
temperature. The same single components were used for classical IC31®, but they 
were mixed in 110mM Tris/135mM NaCl buffer. The classical IC31® was used only 
once for the screening for immunogenicity of tumor-derived antigenic peptides. 
The nano formulation of IC31® in 2.5mM Tris buffer was used in all other 
experiments. 
In two experiments Cholera Toxin B Subunit (CTB) was used as adjuvant 
control for intranasal vaccination (1µg/mouse).  
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7.1.6.  Peptides 
 The peptides were synthesized by Think Peptides (USA). They were 
dissolved in DMSO and stored at -20°C until use. 
HBc    TPPAYRPPNAPIL 
SVN18-27 RISTFKNWPK 
SVN19-28 IATFKNWPFL 
SVN53-67 DLAQCFFCFKELEGW  
SVN57-64  CFFCFKEL  
SVN82-89 SGCAFLSV 
TRP-2180-188   SVYDFFVWL 
 
 
7.2.    Vaccination of mice 
All in-vivo work was done by Berhard Roeder of the Quality Control – In 
Vivo (QC-IV) department.  
The amount of antigen delivered to each mouse was 60µg. The volume for 
subcutaneous and intra dermal injection was 100µl at the tail base. Intramuscular 
(i.m.) immunization was given two times 50µl at the hind limbs and for 
intraperitoneal (i.p.) the volume for vaccination was 100µl.  
The volume for intranasal vaccination was 40µl per mouse. For intranasal 
administration Isofluran was used as anesthesia. Immunizations were performed 
on day 0, 14 and 28 (±1-2 days). 
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7.3.   Methods 
All methods were performed according to the respective SOPs used at 
Intercell AG. 
 
7.3.1.  Preparation of single cell suspensions of murine spleens and lymph 
nodes 
Bernhard Roeder of the QC-IV department sacrificed the mice by cervical 
dislocation. Spleens and draining lymph nodes were harvested and pooled from all 
mice of the same experimental group. Single cell suspensions of spleens or 
draining lymph nodes were prepared by grinding through a cell strainer into a petri 
dish by using the plunger of a syringe. The plunger and the cell strainer were 
washed with complete medium and the cell suspension was transferred into a 
15ml Falcon tube. After centrifugation (1200rpm, 10minutes) supernatant was 
removed by aspirating. For lysis of erythrocytes in spleen cell suspension, red 
blood cell lysis buffer was used (1ml/spleen). After 2 minutes the reaction was 
stopped by adding complete medium. Single cell suspensions were again 
centrifuged (1200rpm, 10 minutes) and supernatants were removed by aspirating. 
For the lymph nodes lysis of erythrocytes was not necessary. Cells were 
resuspended in complete medium. The cell number was determined by trypan 
blue exclusion staining via hemocytometer method. 
 
 
7.3.2.  Preparation of single cell suspension of lungs with Lymphocyte 
Separation Medium  
Bernhard Roeder of the QC-IV department sacrificed the mice by cervical 
dislocation. Lungs were collected and pooled from all mice of the same 
experimental group into a 50ml Falcon tube with 25ml complete medium. Single 
cell suspensions of the lungs were prepare with a homogenizer and passed 
through a 100-µm pore size mesh cell strainers (BD Biosciences). In a new 50ml 
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Falcon tube, 20ml Lymphocyte Separation Medium (LSM) were prepared and 
carefully overlaid with the cell suspension. To create a gradient, cell suspension 
was centrifuged (2000rpm; 20minutes; without brake). 
In advance, Lung mononuclear cells (LMNC) ring was carefully removed 
and complete medium was added. Cells were again centrifuged (2000rpm; 10 
minutes; with brake) and supernatant was aspired. The pellet was resuspended in 
complete medium and centrifuged (1500rpm; 5 minutes). Supernatant was 
aspired. For lysis of erythrocytes in cell suspension red blood cell lysis buffer was 
used (1ml). After 1 minute the reaction was stopped by adding 20ml complete 
medium. Single cell suspensions were again centrifuged (1500rpm, 5 minutes) 
and supernatants were removed by aspirating. Cell pellet was resuspended in 5ml 
complete medium. The cell number was determined by trypan blue exclusion 
staining via hemocytometer method. 
 
 
7.3.3. Preparation of single cell suspension of lungs without Lymphocyte 
Separation Medium  
Bernhard Roeder of the QC-IV department sacrificed the mice by cervical 
dislocation. Lungs were collected and pooled from all mice of the same 
experimental group into a 50ml Falcon tube with 25ml complete medium. Single 
cell suspensions of the lungs were prepare with a homogenizer and passed 
through a 100-µm pore size mesh cell strainers (BD Biosciences). Cells were 
centrifuged (1500rpm, 5 minutes; with brake) and supernatant was aspired. The 
pellet was resuspended in complete medium and centrifuged (1500rpm, 5 
minutes). Supernatant was aspired. For lysis of erythrocytes in cell suspension red 
blood cell lysis buffer was used (5ml). After 1 minute the reaction was stopped by 
adding complete medium. Single cell suspensions were centrifuged (1500rpm, 5 
minutes) and supernatants were removed by aspirating. Cell pellet was 
resupended in 5ml complete medium and passed through a 100-µm pore size 
mesh cell strainers again. The cell number was determined by trypan blue 
exclusion staining via hemocytometer method. Cells observed to be too small 
were excluded from the counting. 
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7.3.4.  MACS cell sorting 
In advance to the preparation of cell suspensions of lungs without the use 
of LSM, the cell numbers were determined by using hemocytometer method. Cells 
were centrifuged (300g, 10minutes). Supernatantes were aspired and cells were 
resuspended in 500µl ice cold MACS buffer and 20µl of Biotin Antibody Cocktail (T 
Pan Isolation Kit). More MACS buffer and Biotin-Antibody Cocktail were used than 
described in the protocol of Miltenyi Biotec, because the pellets were bigger than 
expected. Cell suspensions were incubated for 10 minutes at 4°C. The reaction 
was stopped by adding MACS buffer. 40µl of Anti-Biotin MicroBeads were added. 
Cells were incubated for 15minutes at 4°C.  Cells were washed with 2ml buffer 
and centrifuged (300g, 10minutes). In the meanwhile the cold columns were pre-
rinsed with ice cold MACS buffer. Supernatants were aspired and pellets were 
resupended in 50µl MACS buffer. Columns were loaded and four times washed 
with buffer. To separate CD8+ cells and CD4+ cells, 10µl per 107 total cells of CD4 
(L3T4) microbeads were added after centrifuged the cell suspension (300g, 
10minutes). Cells were incubated for 15minutes at 4°C. Cells were washed with 
5ml MACS buffer. In the meanwhile the columns were prepared and again pre-
rinsed with ice cold buffer.  Cell pellets were resuspended in 1ml of ice cold buffer 
and columns were loaded. CD8+ cells were collected in a tube and counted with 
hemocytometer method. An aliquot of each sample was stained with CD8+ PE and 
CD4+ FITC (1:200 dilutions in MACS buffer). Each stained sample was measured 
on FACSCalibur. 50.000 events were counted from the lymphocyte gate. The data 
were analyzed by the use of the FCS Express 3 Software to make sure that only 
CD8+ T cells were used for further analysis. 
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7.3.5.  IFN-  ELIspot assay 
 Multiscreen-HTS filter plates (Cat-N° MSHAS4510, Millipore) were pre-
rinsed by adding sterile 1x PBS and coated with rat anti-mouse IFN-γ antibody. 
The antibody was diluted to a final concentration of 3µg/ml in coating buffer (pH 
9.2-9.4) which consisted of 0.1M NaHCO3 in aqua distillate. Plates were incubated 
over night at 4°C in a wet chamber. Before plating the cells, plates were blocked 
for 1 hour at 37 °C with blocking buffer, which consisted of 1% BSA in 1x PBS. 
 In advance to the blocking step 0.25-1.0x106 cells were plated (100µl/well) 
in triplicates and stimuli (100µl/well) were added. As respective controls the cells 
were restimulated with ConA as positive control (1µg/ml), complete medium as 
negative control and an irrelevant peptide (1µg/ml) for specifity. Plates were 
incubated over night at 37°C (5% CO2). 
The next day, cells were discarded from ELIspot plates. Plates were 
washed three times with washing buffer which consisted of 0.1% Tween20 in 
1xPBS. The second biotin anti-mouse IFN-  antibody was prepared by diluting to a 
final concentration of 1µg/ml in 1x PBS and adding to each well. Plates were 
incubated for 2 hours at 37°C (5% CO2). After the washing step Streptavidin-
labeled horseradish peroxidase (SA-HPO) was added and incubated at 37°C (5% 
CO2) for 30min. After washing, the substrate which consisted of 0.8mg/ml 
3,3’diaminobenzidine (DAB) , 0.4mg/ml NiCl2 and 0.015% H2O2 in 0.1M Tris, was 
added. 
The reaction was performed at room temperature until the spots became 
clearly visible. It was stopped by washing plates under running water. The plates 
were dried at RT. Spots from dry plates were counted by Bioreader 5000. 
 
 
7.3.6. IL-4 ELIspot assay 
IL-4 ELIspot assay was performed as described for IFN-γ ELIspot assay. 
Multiscreen-HTS filter plates (Cat. N°: MSIPS4510, Millipore) were used for the 
assay. The primary rat anti-mouse IL-4 antibody was used at a final concentration 
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of 2µg/ml in coating buffer. The secondary biotin anti-mouse IL-4 antibody, was 
diluted to a concentration of 1µg/ml in 1x PBS. 
 
 
7.3.7. Flow cytometry – Intracellular Cytokine Staining 
   For the Intracellular Cytokine Staining 1x106 cells (50µl) derived from 
spleen were plated in triplicates in a 96-well U-bottom plate (Nunc). The cells were 
centrifuged (1200rpm, 5minutes). The supernatants were discarded and the pellet 
was resuspended in 50µl complete medium without 5% FBS.  
In advance 50µl of stimuli were added (1µg/ml). As controls, complete 
medium without 5% FBS was used as negative control. As positive control 1µg/ml 
PMA/Iono was added to respective wells. Following 1.5 hours stimulation, Golgi 
Plug was added in a 1:1000 dilution in complete medium without 5% FBS (100µl) 
to the cells. After 3.5 hours, cells were washed with MACS buffer and centrifuged 
2 min at 2100rpm. Cells were incubated 10minutes at 4°C with FC block (purifies 
anti-mouse CD16/31 blocks Fc binding) (1µg/1x106 cells; clone 2.4G2), to block 
non-specific bindings. Cells were washed once with MACS buffer and centrifuged 
at 2100rpm for 2minutes. The supernatant was carefully removed by inverting the 
plate on a paper towel. After the washing step, surface staining was performed by 
adding 100µl/well of the CD8a antibody. The antibody was diluted to a final 
concentration of 2µg/ml with MACS buffer. The cells were incubated for 20 
minutes at 4°C in the dark. The corresponding isotype control (2µg/ml) was used 
as well. Cells were washed once again with 100µl MACS buffer and plate was 
centrifuged at 2100rpm for 2 minutes. Supernatants were discarded. To 
permeabilize the cell membrane Cytoperm/Cytofix was added for 10-15 minutes. 
For the next two washing steps 100µl Perm/Wash (1:10 dilution with aqua 
distillate) was added to each respective well and the plate was again centrifuged 
at 2100rpm for 2 minutes. Subsequent the intracellular staining was performed by 
adding 100µl/well cytokine specific antibodies (see table 6). The antibodies were 
diluted to a final concentration of 2µg/ml with Perm/Wash. Corresponding isotypes 
for each cytokine antibodies were added at the same time to respective wells (see 
table 6). The staining took 30 minutes at 4°C in the dark. After finishing the 
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intracellular cytokine staining the cells were washed once with Perm/Wash and 
once with MACS buffer. The cell pellets were diluted in 100µl MACS buffer and the 
triplicates were pooled in the FACS tube.  The samples were kept at 4°C and on 
the next day the cells were measured on FACSCalibur. 500.000 events were 
counted from the lymphocyte gate. The data were analyzed by the use of the FCS 
Express 3 Software and CXP Software. 
 
 
7.3.8. Flow cytometry – Granzyme B staining 
The Granzyme B staining was performed like the Intracellular staining. 
After plating, the cells were stimulated for 16 hours at 37°C (5% CO2).In advance 
to this incubation time, 100µl Golgi Plug (1:50 diluted in complete medium without 
5% FBS) were added to each respective well and cells were again incubated for 4 
hours at 37°C (5% CO2). Before washing with MACS buffer the triplicates were 
pooled and afterwards the procedure for the surface staining was performed like 
described in 8.3.6.. The antibody for the surface staining was diluted to a final 
concentration of 1µg/ml with MACS buffer (see table 6). For the Intracellular 
staining Granzyme B antibody (see table 6) was diluted with Perm/Wash to 
1µg/ml. 
 
 
7.3.9. FlowCytomixTM 
For the FlowCytomixTM, cells from spleens, lymph nodes and lungs were 
plated and stimulated for 48 hours at 37°C (5% CO2). ConA was used as positive 
control, complete medium as negative control and antigens as relevant or 
irrelevant peptide (1µg/ml). Cells were centrifuged at 2100rpm for 2 minutes at 
4°C. Supernatants were transferred into a new plate and stored at -20°C until they 
were used. 
For the FlowCytomixTM a Mouse Th1/Th2 10plex Kit (eBioscience) was 
used. First, all solutions were prepared. The Assay Buffer (10x) was diluted with 
distilled water to 1x. Afterwards the lyophilized Standards were reconstituted by 
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adding respective amount of distilled water and incubated them for 30 minutes 
before pipetting at RT. In the meanwhile Bead Mixture was prepared. All vials 
were vortexed well, before 150µl were added to 1500µl Assay Buffer.  The beads 
were centrifuged with 4000rpm for 5 minutes at room temperature. 2950µl of the 
supernatant were removed and the same amount of Assay buffer was used to 
resuspend the pellet. Afterwards, the Conjugation Mix was prepared. Every vial 
was vortexed very well and 300µl of each was added to 3000µl Assay Buffer. The 
30 minutes of incubation were over and a standard dilution series were twice 
prepared. 
 In advance, the filter plate was pre-wetted with 50µl Assay buffer. By using 
the vacuum filtration manifold (Millipore) the Assay buffer was aspired. 
Subsequent 25µl of the standard dilution series and the samples were plated. Two 
wells were used as blanks, were only Assay buffer was added, and one well was 
used for the Setup Standard 1, which was designated for cytometer setup. 25µl of 
Bead Mixture were added to each well and 50ml of Biotin-Conjugate Mixture. The 
plate was wrapped with aluminium foil and put on the shaker for 2 hours at RT. 
After these two hours incubation time, the Streptavidin-PE solution was 
prepared. The wells were emptied using the vacuum filtration manifold. The plate 
was washed two times with 100µl Assay Buffer and again emptied with the 
vacuum filtration manifold. Afterwards 100µl Assay Buffer was added to each 
respective well, as well as 50µl Streptavidin-PE Solution. The plate was wrapped 
with aluminium foil and incubated for 1 hour on the shaker at RT.  Subsequent, the 
wells were again emptied and washed two times as done before. 300µl Assay 
Buffer was put in every prepared FACS tube. To each well of the plate 200µl 
Assay Buffer were added. The 200µl were transferred into a separate acquisition 
tube for the flow cytometer. The setup beads were designed for cytometer setup 
and 500µl were put into one separate labeled tube. 
  Afterwards the samples were measured on FACSCalibur. 1500 events 
were counted. The data were analyzed by the use of the FlowCytomix Pro 
Software. 
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